Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

35
results for

"Asia"

Article category

Keywords

Publication year

"Asia"

Special Review

Liver disease trends in the Asia-Pacific region for the next 50 years
Shuichiro Shiina, Javkhlan Maikhuu, Qing Deng, Terguunbileg Batsaikhan, Lariza Marie Canseco, Maki Tobari, Hitoshi Maruyama, Hiroaki Nagamatsu, Diana Alcantara-Payawal, Rino Gani, Yi-Hsiang Huang, Tawesak Tanwandee, Giovanni Galati, Yoon Jun Kim
Clin Mol Hepatol 2025;31(3):671-684.
Published online March 4, 2025
DOI: https://doi.org/10.3350/cmh.2025.0043
Liver disease has emerged as a critical and escalating public health concern worldwide, with the Asia-Pacific region at the forefront of this challenge due to its vast population and diverse socioeconomic landscape. Over the coming five decades, this region will experience profound changes in liver disease patterns, shaped by rapid urbanization, lifestyle modifications, advancements in medical technologies, and evolving public health strategies. This article offers an in-depth analysis of six transformative areas defining the trajectory of liver disease in the region. First, it highlights the alarming rise of metabolic dysfunction-associated fatty liver disease and metabolic dysfunction-associated steatohepatitis, diseases driven by modern lifestyle factors and inherent metabolic susceptibilities. Concurrently, it celebrates the declining burden of viral hepatitis, underscoring the success of sustained public health interventions. However, new challenges are emerging, such as the growing impact of environmental and occupational exposures on liver health. Breakthroughs in genomic and epigenetic research promise to advance precision medicine, offering targeted therapeutic solutions. Additionally, the integration of artificial intelligence, big data, and telemedicine is poised to revolutionize liver disease management, improving accessibility and personalized care. Finally, the article emphasizes the critical role of robust health policies, preventive strategies, and cross-border collaboration in shaping a healthier future. By synthesizing these insights, the study aims to guide innovative and effective responses to the evolving liver disease landscape in the Asia-Pacific region.

Citations

Citations to this article as recorded by  Crossref logo
  • Digital divide and healthcare service utilization among older adults with chronic liver disease in China: a nationwide cross-sectional study
    Yang Feng, Ke Pu, Chang Liu
    Scientific Reports.2026;[Epub]     CrossRef
  • Association Between Sarcopenic Obesity–Related Scores and Liver Fibrosis in Patients with Steatotic Liver Disease: A Cross-Sectional Study
    Tatsuki Ichikawa, Satoshi Miuma, Mio Yamashima, Shinobu Yamamichi, Makiko Koike, Yusuke Nakano, Hiroyuki Yajima, Osamu Miyazaki, Tomonari Ikeda, Takuma Okamura, Naohiro Komatsu, Mayuko Kakizoe, Ryusei Tanaka, Hisamitsu Miyaaki
    Diagnostics.2026; 16(2): 324.     CrossRef
  • Trends and future projections of liver cancer attributable to metabolic dysfunction-associated steatohepatitis in China from 1990 to 2050
    Jincheng Tang, Renyi Yang, Kexiong Li, Wei Peng, Zuomei He, Wenhui Gao, Puhua Zeng
    Scientific Reports.2025;[Epub]     CrossRef
  • Bridging the Gap in Elimination of Hepatitis C Virus among People Who Use Drugs in South Korea
    Beom Kyung Kim
    Gut and Liver.2025; 19(5): 635.     CrossRef
  • Precision prevention of liver cancer based on risk factors
    Jian-Guo Chen
    Exploration of Digestive Diseases.2025;[Epub]     CrossRef
  • MAFLD in Vietnam: a neglected public health challenge requiring urgent policy action
    Thong Duy Vo, Huong Tu Lam
    Frontiers in Clinical Diabetes and Healthcare.2025;[Epub]     CrossRef
  • 10,610 View
  • 219 Download
  • 5 Web of Science
  • Crossref

Review

Hepatic neoplasm

Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison
Yuri Cho, Bo Hyun Kim, Joong-Won Park
Clin Mol Hepatol 2023;29(2):252-262.
Published online March 10, 2023
DOI: https://doi.org/10.3350/cmh.2023.0099
Hepatocellular carcinoma (HCC) is highly prevalent and the third most common cause of cancer-related death in Asia. In contrast to the West, the main etiology of HCC in many Asian countries except Japan is chronic hepatitis B virus infection. Differences in the major causes of HCC lead to significant clinical and treatment differences. This review summarizes and compares guidelines on managing HCC from China, Hong Kong, Taiwan, Japan, and South Korea. From oncology and socio-economic perspectives, factors such as underlying diseases, staging methods, government policies, insurance coverage, and medical resources contribute to varying treatment strategies among countries. Furthermore, the differences in each guideline are fundamentally caused by the lack of incontrovertible medical evidence, and even existing results of clinical trials can be interpreted differently. This review will provide a complete overview of the current Asian guidelines for HCC in recommendations and in practice.

Citations

Citations to this article as recorded by  Crossref logo
  • Impact of Add‐On Hepatobiliary Abbreviated Magnetic Resonance Imaging on Ultrasound Hepatoma Surveillance for Liver Cirrhosis‐ a Randomized Study
    Jing‐Houng Wang, Hsin‐You Ou, Yi‐Hao Yen, Chao‐Hung Hung, Sheng‐Nan Lu
    The Kaohsiung Journal of Medical Sciences.2026;[Epub]     CrossRef
  • Clinical outcomes of carbon-ion radiotherapy for residual or recurrent hepatocellular carcinoma after transarterial chemoembolization
    Y. Sekiguchi, K. Shibuya, S. Tomogane, Y. Miyasaka, S. Kakizaki, M. Okamoto, K. Araki, K. Shirabe, T. Ohno
    ESMO Gastrointestinal Oncology.2026; 11: 100280.     CrossRef
  • Survival and safety outcomes of hepatectomy versus ablation in hepatocellular carcinoma within Milan criteria and clinically significant portal hypertension: a systematic review and meta-analysis
    Yong-Hao Wen, Yu-Min Yang, Jing-Xin Yan, Peng Gu, Yan-Qi Tai, Jin-Yu Li, Yun-Long Duan, Man-Jun Deng, Hai-Ning Fan
    International Journal of Surgery.2026;[Epub]     CrossRef
  • Identifying Sorafenib Benefit among Hepatocellular Carcinoma Patients: A Transcriptomic and Genomic Approach
    Sun Young Yim, Hayeon Kim, Tae Hyung Kim, Sang-Hee Kang, Youngwoo Lee, Eunho Choi, Yang Jae Yoo, Seong Hee Kang, Young-Sun Lee, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kyung Suk Yang, Yitao Tang, Bowha Sohn, Yun Seong Jeong, Hyewon P
    JHEP Reports.2026; : 101742.     CrossRef
  • Targeting Wnt3a and Loxl2 Synergistically Induces Ferroptosis in Liver Cancer Stem Cells and Suppresses Tumorigenesis
    Guanghui Ren, Qingwei Cong, Jing Wang, Wenyue Gao, Yunpeng Guan, Lianxin Zhu, Ying Zhu
    Cancer Science.2026;[Epub]     CrossRef
  • SPARC: A programmable molecular diagnostic platform based on a signal-triggered, self-supplied crRNA and tiered PER-transcription-CRISPR cascade for early detection of hepatocellular carcinoma
    Xinying Chang, Cong Han, Haishuo Ji, Zhe Zeng, Jingyi Yang, Qirui Liu, Chao Jia, Lili Zhao, Chunlei Zhou, Shujia Chen, Wolfgang Knoll, Jia Li, Zhenglu Wang, Liyun Zhang
    Analytica Chimica Acta.2026; 1394: 345209.     CrossRef
  • Comparison of Metastasectomy and Stereotactic Body Radiation Therapy for Pulmonary Oligometastasis From Hepatocellular Carcinoma: A Propensity Score-Weighted Analysis
    Young Seob Shin, Jae Kwang Yun, Jinhong Jung, Jin-hong Park, Si Yeol Song, Eun Kyung Choi, Sehoon Choi, Hyeong Ryul Kim, Yong-Hee Kim, Dong Kwan Kim, Geun Dong Lee, Sang Min Yoon
    International Journal of Radiation Oncology*Biology*Physics.2025; 121(2): 432.     CrossRef
  • Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
    Bruno Sangro, Masatoshi Kudo, Joseph P Erinjeri, Shukui Qin, Zhenggang Ren, Stephen L Chan, Yasuaki Arai, Jeong Heo, Anh Mai, Jose Escobar, Yamil Alonso Lopez Chuken, Jung-Hwan Yoon, Won Young Tak, Valeriy V Breder, Tanita Suttichaimongkol, Mohamed Bouatt
    The Lancet.2025; 405(10474): 216.     CrossRef
  • Correspondence to letter to the editor on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis”
    Moon Haeng Hur, Yoon Jun Kim
    Clinical and Molecular Hepatology.2025; 31(1): e93.     CrossRef
  • APAGE Position Statements on Green and Sustainability in Gastroenterology, Hepatology, and Gastrointestinal Endoscopy
    Tiing Leong Ang, Dao Viet Hang, James Weiquan Li, Jacky Chiu Leung Ho, Marianne Linley Sy‐Janairo, Raja Affendi Raja Ali, Govind K. Makharia, Sridhar Sundaram, Tanyaporn Chantarojanasiri, Hyun‐Gun Kim, Hiroyuki Isayama, Nonthalee Pausawasdi, Kaichun Wu, A
    Journal of Gastroenterology and Hepatology.2025; 40(4): 821.     CrossRef
  • Transarterial chemoembolization in hepatocellular carcinoma: exploring its role in vascular invasion and extrahepatic metastasis: A systematic review
    Muhammad Usman Younas, Abdullah Saeed, Muhammad Ramzan, Muhammad Junaid Tahir, Khabab Abbasher Hussien Mohamed Ahmed, Ali Ahmed
    Medicine.2025; 104(8): e41570.     CrossRef
  • Plasma protein levels and hepatocellular carcinoma: a Mendelian randomization study with drug screening implications
    Longhui Xie, Dekun Song, Jianwei Lan, Pengpeng Liu, Shuang Qin, Yinkuan Ning, Quanyan Liu
    Discover Oncology.2025;[Epub]     CrossRef
  • Quantitative Ablation Confirmation Methods in Percutaneous Thermal Ablation of Malignant Liver Tumors: Technical Insights, Clinical Evidence, and Future Outlook
    Iwan Paolucci, Jessica Albuquerque Marques Silva, Yuan-Mao Lin, Alexander Shieh, Anna Maria Ierardi, Gianpaolo Caraffiello, Carlo Gazzera, Kyle A. Jones, Paolo Fonio, Reto Bale, Kristy K. Brock, Marco Calandri, Bruno C. Odisio
    Radiology: Imaging Cancer.2025;[Epub]     CrossRef
  • Long‐Term Survival and Prognostic Factors of Stereotactic Body Radiotherapy Following Transarterial Chemoembolization for Hepatocellular Carcinoma
    Hoang Dong Duc, Mai Binh Thanh, Mai Bang Hong, Nguyen Thinh Tien, Nguyen Thai Van, Bui Bieu Quang, Nguyen Chau Dinh, Thai Ky Doan
    Cancer Reports.2025;[Epub]     CrossRef
  • Association between early job loss and prognosis among hepatocellular carcinoma survivors
    B Yun, J Oh, S H Ahn, B K Kim, J-H Yoon
    Occupational Medicine.2025; 75(2): 113.     CrossRef
  • Spinal Cord Infarction After Transarterial Chemoembolization for Hepatocellular Carcinoma: A Case Report
    Tho Tran Dinh, Sy Than Van, Vinh Chu Van, Phuc Chu Minh
    Cureus.2025;[Epub]     CrossRef
  • Imaging-based diagnosis of hepatocellular carcinoma: Liver Imaging Reporting and Data System and beyond
    Maryam Haghshomar, Andrea S Kierans, Laura Kulik, Frank H Miller, Amir A Borhani
    British Journal of Radiology.2025; 98(1173): 1344.     CrossRef
  • Tumor size larger than 6.5 cm and microvascular invasion are comparable prognosticators for hepatocellular carcinoma: a multi-institutional observational study
    Hsing-Yu Chen, Hsin-I Tsai, Ming-Chin Yu, Wei-Chen Lee, Chih-Chi Wang, Jason Chia-Hsun Hsieh, Chiao-En Wu, Po-Ting Lin, Bo-Huan Chen, Sheng-Fu Wang, Chao-Wei Lee
    Clinical and Translational Oncology.2025; 28(1): 215.     CrossRef
  • Outcome of hepatic resection for HCC in ideal and non-ideal candidates
    Lorenzo Lani, Laura Bucci, Valentina Santi, Benedetta Stefanini, Bernardo Stefanini, Angelo Sangiovanni, Sara Grasselli, Giorgia Ghittoni, Carlo Saitta, Filomena Morisco, Giuseppe Cabibbo, Fabio Marra, Gianpaolo Vidili, Maurizia Rossana Brunetto, Francesc
    Hepatology Communications.2025;[Epub]     CrossRef
  • The construction and evaluation of a prognostic risk score model for HCC based on MPT-related lncRNAs
    Zerun Lin, Jianda Yu, Zhijian Chen, Jingyi Chen, Xiaobin Chi, Honghuan Lin, Yongbiao Chen
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Serum Level of Glypican-3 in Patients with Hepatocellular Carcinoma and Advanced Chronic Liver Disease: A Pilot Study
    Irina Ivanova, Sonya Banova-Chakyrova, Pavlina Boykova-Vylcheva, Yana Bocheva
    Livers.2025; 5(3): 36.     CrossRef
  • Surgical treatment of hepatocellular carcinoma: an expert consensus-based practical recommendation from the Korean Liver Cancer Association
    Min-Su Park, Jai Young Cho, Eunju Kim, Hee Young Na, YoungRok Choi, Na Reum Ki, Young-In Yoon, Boram Lee, Eun Sun Jang, Yun Kyung Jung, Kyung Sik Kim
    Annals of Surgical Treatment and Research.2025; 109(3): 123.     CrossRef
  • Machine Learning–Based Selection of Resection vs Transplant and Survival in Hepatocellular Carcinoma
    Hyun Uk Kim, Ji Won Han, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Ho Joong Choi, Young Kyoung You
    JAMA Network Open.2025; 8(9): e2532353.     CrossRef
  • Public health strategies for hepatocellular carcinoma: from risk factors to prevention and control
    Mei-Hsuan Lee
    Journal of Liver Cancer.2025; 25(2): 204.     CrossRef
  • Hepatocellular carcinoma: Epidemiology, diagnosis and treatment
    Ezequiel Mauro, Tiago de Castro, Marcus Zeitlhoefler, Max W. Sung, Augusto Villanueva, Vincenzo Mazzaferro, Josep M. Llovet
    JHEP Reports.2025; 7(12): 101571.     CrossRef
  • A Patient Charter to Improve Care for Hepatocellular Carcinoma
    Yasmine Hassan, Achim Kautz, Cary James, Dee Lee, Diane Langenbacher, Eric Bouffet, Jade Chakowa, Jessica Hicks, John Ward, Lili Kuschnereit, Manon Allaire, Tingting Zhang, Zeena Huang Chi
    Journal of Hepatocellular Carcinoma.2025; Volume 12: 1849.     CrossRef
  • Prognostic Role of Short-Chain Fatty Acid-Producing Gut Microbiota and Gut Microbial Dynamics in Patients with Hepatocellular Carcinoma Receiving Chemoembolization: A Prospective Study
    Jiwon Yang, Jihye Lim, Eun Hye Kim, Jihyun An, Danbi Lee, Han Chu Lee, Jin-Yong Jeong, Ju Hyun Shim
    Journal of Hepatocellular Carcinoma.2025; Volume 12: 1991.     CrossRef
  • Immune Checkpoint Inhibitor Use in Advanced Hepatocellular Carcinoma: A Real-World Analysis of Efficacy and Toxicity
    Fode Tounkara, Deepak Sherpally, Khalid Mumtaz, Mina S. Makary, Russell F. Palm, Ashish Manne
    Cancers.2025; 17(18): 3034.     CrossRef
  • Surgical treatment of hepatocellular carcinoma: an expert consensus-based practical recommendation from the Korean Liver Cancer Association
    Min-Su Park, Jai Young Cho, Eunju Kim, Hee Young Na, YoungRok Choi, Na Reum Kim, Young-In Yoon, Boram Lee, Eun Sun Jang, Yun Kyung Jung, Kyung Sik Kim
    Journal of Liver Cancer.2025; 25(2): 140.     CrossRef
  • GALAD score accuracy in detection of hepatocellular carcinoma in cirrhotic patients: a single-center study
    Mina Tharwat, Yosra Yosry, Islam Nakeeb, Sahar Hassany
    The Egyptian Journal of Internal Medicine.2025;[Epub]     CrossRef
  • Dynamic Muscle Atrophy Predicts Outcomes in Patients with Unresectable Hepatocellular Carcinoma Treated with First-Line Lenvatinib: A Retrospective Study in Taiwan
    Hsing-Yun Lee, Ching-Di Chang, Yen-Hao Chen, Ming-Chao Tsai, Jing-Houng Wang, Sheng-Nan Lu, Tsung-Hui Hu, Chao-Hung Hung, Chien-Hung Chen, Yuan-Hung Kuo
    Gut and Liver.2025; 19(6): 878.     CrossRef
  • Decoding the epigenetic landscape: ctDNA methylation as a game-changer in hepatocellular carcinoma management
    Dexin Yang, Yueru Yao, Fenfang Gui, Wuxuan Mei, Changchun Zeng
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2025; 1880(6): 189497.     CrossRef
  • Investigating Alternative Treatment Options Unfeasible for Local Ablation Therapy in Patients with Small Solitary Hepatocellular Carcinomas
    Chang Hun Lee, In Hee Kim
    Gut and Liver.2024; 18(1): 5.     CrossRef
  • RNA 5-methylcytosine writer NSUN5 promotes hepatocellular carcinoma cell proliferation via a ZBED3-dependent mechanism
    Xinyu Gu, Penghui Li, Xiaohui Gao, Yi Ru, Chen Xue, Shujun Zhang, Yafeng Liu, Xinjun Hu
    Oncogene.2024; 43(9): 624.     CrossRef
  • Letter regarding “Treatment options for solitary hepatocellular carcinoma ≤5 cm: surgery vs. ablation: a multicenter retrospective study”
    Jongman Kim
    Journal of Liver Cancer.2024; 24(1): 3.     CrossRef
  • Liver cancer surveillance in people with hepatitis B in Africa
    Dennis A Ndububa
    The Lancet Gastroenterology & Hepatology.2024; 9(6): 491.     CrossRef
  • SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea
    Hyo Jung Cho, Eunyoung Lee, Soon Sun Kim, Jae Youn Cheong
    Scientific Reports.2024;[Epub]     CrossRef
  • Intrahepatic IgA complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of HCC
    Jong Geun Park, Pu Reun Roh, Min Woo Kang, Sung Woo Cho, Suhyun Hwangbo, Hae Deok Jung, Hyun Uk Kim, Ji Hoon Kim, Jae-Sung Yoo, Ji Won Han, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Young Kyoung You, Ho Joong Choi, Jae Yong Ryu, Pil Soo Sung
    Hepatology.2024; 80(5): 1074.     CrossRef
  • Current perspectives of viral hepatitis
    Daisuke Usuda, Yuki Kaneoka, Rikuo Ono, Masashi Kato, Yuto Sugawara, Runa Shimizu, Tomotari Inami, Eri Nakajima, Shiho Tsuge, Riki Sakurai, Kenji Kawai, Shun Matsubara, Risa Tanaka, Makoto Suzuki, Shintaro Shimozawa, Yuta Hotchi, Ippei Osugi, Risa Katou,
    World Journal of Gastroenterology.2024; 30(18): 2402.     CrossRef
  • Recent Hepatocellular Carcinoma Managements in Korea: Focus on the Updated Guidelines in 2022
    Yuri Cho, Bo Hyun Kim, Young-Suk Lim
    Digestive Disease Interventions.2024; 08(03): 169.     CrossRef
  • Research Progress on the Role of Epigenetic Methylation Modification in Hepatocellular Carcinoma
    Jing Wang, Wenyue Gao, Hongbo Yu, Yuting Xu, Changchuan Bai, Qingwei Cong, Ying Zhu
    Journal of Hepatocellular Carcinoma.2024; Volume 11: 1143.     CrossRef
  • Establishment of nomogram prediction model of contrast-enhanced ultrasound and Gd-EOB-DTPA-enhanced MRI for vessels encapsulating tumor clusters pattern of hepatocellular carcinoma
    Feiqian Wang, Kazushi Numata, Akihiro Funaoka, Xi Liu, Takafumi Kumamoto, Kazuhisa Takeda, Makoto Chuma, Akito Nozaki, Litao Ruan, Shin Maeda
    BioScience Trends.2024; 18(3): 277.     CrossRef
  • Limited Generalizability of Retrospective Single-Center Cohort Study in Comparison to Multicenter Cohort Study on Prognosis of Hepatocellular Carcinoma
    Ye Rim Kim, Sung Won Chung, Min-Ju Kim, Won-Mook Choi, Jonggi Choi, Danbi Lee, Han Chu Lee, Ju Hyun Shim
    Journal of Hepatocellular Carcinoma.2024; Volume 11: 1235.     CrossRef
  • Clinical Parameters Work Well as Predictive Factors for Atezolizumab and Bevacizumab Treatment in Hepatocellular Carcinoma
    Ji Yeon Lee, Pil Soo Sung
    Gut and Liver.2024; 18(4): 558.     CrossRef
  • Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions
    Lung-Yi Mak, Ken Liu, Sakkarin Chirapongsathorn, Kuo Chao Yew, Nobuharu Tamaki, Ruveena Bhavani Rajaram, Mara Teresa Panlilio, Rashid Lui, Hye Won Lee, Jimmy Che-To Lai, Anand V. Kulkarni, Madhumita Premkumar, Cosmas Rinaldi Adithya Lesmana, Yao Chun Hsu,
    Nature Reviews Gastroenterology & Hepatology.2024; 21(12): 834.     CrossRef
  • Liver resection and transplantation in the era of checkpoint inhibitors
    Parissa Tabrizian, Rebecca Marino, Pierce K.H. Chow
    JHEP Reports.2024; 6(11): 101181.     CrossRef
  • Global epidemiology of liver cancer 2022: An emphasis on geographic disparities
    Qianru Li, Chao Ding, Maomao Cao, Fan Yang, Xinxin Yan, Siyi He, Mengdi Cao, Shaoli Zhang, Yi Teng, Nuopei Tan, Jiachen Wang, Changfa Xia, Wanqing Chen
    Chinese Medical Journal.2024; 137(19): 2334.     CrossRef
  • Similar recurrence after curative treatment of HBV-related HCC, regardless of HBV replication activity
    Mi Na Kim, Beom Kyung Kim, Heejin Cho, Myung Ji Goh, Yun Ho Roh, Su Jong Yu, Dong Hyun Sinn, Soo Young Park, Seung Up Kim, Tyng-Yuan Jang
    PLOS ONE.2024; 19(8): e0307712.     CrossRef
  • Heavy smoking increases early mortality risk in patients with hepatocellular carcinoma after curative treatment
    Jaejun Lee, Jong Young Choi, Soon Kyu Lee
    Journal of Liver Cancer.2024; 24(2): 253.     CrossRef
  • A Nomogram Based on Features of Ultrasonography and Contrast-Enhanced CT to Predict Vessels Encapsulating Tumor Clusters Pattern of Hepatocellular Carcinoma
    Litao Ruan, Jingtong Yu, Xingqi Lu, Kazushi Numata, Dong Zhang, Xi Liu, Xiaojing Li, Mingwei Zhang, Feiqian Wang
    Ultrasound in Medicine & Biology.2024; 50(12): 1919.     CrossRef
  • Prediction of PD-L1 expression in unresectable hepatocellular carcinoma with gadoxetic acid-enhanced MRI
    Jun Gu Kang, Kyunghwa Han, Taek Chung, Hyungjin Rhee
    European Journal of Radiology.2024; 181: 111772.     CrossRef
  • Long-term outcomes of more than a decade treating patients with stereotactic body radiation therapy for hepatocellular carcinoma
    Wilhelm den Toom, Eva M. Negenman, Francois E.J.A. Willemssen, Erik van Werkhoven, Robert J. Porte, Roeland F. de Wilde, Dave Sprengers, Imogeen E. Antonisse, Ben J.M. Heijmen, Alejandra Méndez Romero
    Clinical and Translational Radiation Oncology.2024; 49: 100878.     CrossRef
  • Reappraisal of transarterial radioembolization for liver-confined hepatocellular carcinoma with portal vein tumor thrombosis: Editorial on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein throm
    Jin Hyoung Kim, Gun Ha Kim, Dong Il Gwon
    Clinical and Molecular Hepatology.2024; 30(4): 659.     CrossRef
  • Combined Bone Mineral Density (BMD) and Monocyte-to-Lymphocyte Ratio (MLR) Predicts Recurrence and Prognosis in Hepatocellular Carcinoma Patients Following Liver Resection
    Ze-Jiao He, Tao Hu, Zi-Shu Zhang, Tian-Cheng Wang, Wei Huang
    Risk Management and Healthcare Policy.2024; Volume 17: 2741.     CrossRef
  • Hepatocellular Carcinoma Surveillance Strategies: Major Guidelines and Screening Advances
    Gavin Wu, Nojan Bajestani, Nooruddin Pracha, Cindy Chen, Mina S. Makary
    Cancers.2024; 16(23): 3933.     CrossRef
  • Resistance to Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma (HCC): Clinical Implications and Potential Strategies to Overcome the Resistance
    Ali Gawi Ermi, Devanand Sarkar
    Cancers.2024; 16(23): 3944.     CrossRef
  • Primary treatments for solitary hepatocellular carcinoma ≤ 3 cm: A systematic review and network meta-analysis
    Sang-Hoon Kim, Ki-Hun Kim, Byeong-Gon Na, Sung Min Kim, Rak-Kyun Oh
    Annals of Hepato-Biliary-Pancreatic Surgery.2024; 28(4): 397.     CrossRef
  • TEAD2 Promotes Hepatocellular Carcinoma Development and Sorafenib Resistance via TAK1 Transcriptional Activation
    Yahui Zhang, Yidan Ren, Guoying Dong, Qinlian Jiao, Nan Guo, Ping Gao, Ya Li, Yunshan Wang, Wei Zhao
    Molecular Cancer Research.2024; 22(12): 1102.     CrossRef
  • Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced MRI improves diagnosis and efficacy evaluation of early-stage hepatocellular carcinoma
    Ya-Yun Wang
    American Journal of Cancer Research.2024; 14(10): 4855.     CrossRef
  • Advances in systemic therapy leading to conversion surgery for advanced hepatocellular carcinoma
    Hiroyuki Hakoda, Akihiko Ichida, Kiyoshi Hasegawa
    BioScience Trends.2024; 18(6): 525.     CrossRef
  • Early-Stage HCC Percutaneous Locoregional Management: East versus West Perspectives
    Roberto Iezzi, Alessandro Posa, Andrea Contegiacomo, In Joon Lee, Reto Bale, Alessandro Tanzilli, Lorenzo Tenore, Felice Giuliante, Antonio Gasbarrini, Shraga Nahum Goldberg, Tobias Jakobs, Maurizio Pompili, Irene Bargellini, Evis Sala, Hyo-Cheol Kim
    Cancers.2023; 15(15): 3988.     CrossRef
  • A Phase I/IIa Trial of Yttrium-90 Radioembolization in Combination with Durvalumab for Locally Advanced Unresectable Hepatocellular Carcinoma
    Yun Bin Lee, Joon Yeul Nam, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Hyo-Cheol Kim, Jin Chul Paeng, Jung-Hwan Yoon, Yoon Jun Kim
    Clinical Cancer Research.2023; 29(18): 3650.     CrossRef
  • Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma?
    Hyo-Cheol Kim
    Clinical and Molecular Hepatology.2023; 29(4): 984.     CrossRef
  • The efficacy of treatment for hepatocellular carcinoma in elderly patients
    Han Ah Lee, Sangheun Lee, Hae Lim Lee, Jeong Eun Song, Dong Hyeon Lee, Sojung Han, Ju Hyun Shim, Bo Hyun Kim, Jong Young Choi, Hyunchul Rhim, Do Young Kim
    Journal of Liver Cancer.2023; 23(2): 362.     CrossRef
  • Multiomics characterization of fatty acid metabolism for the clinical management of hepatocellular carcinoma
    Xin Huang, Benzhe Su, Mengjun Li, Yang Zhou, Xinyu He
    Scientific Reports.2023;[Epub]     CrossRef
  • 12,287 View
  • 320 Download
  • 64 Web of Science
  • Crossref

Editorial

Steatotic liver disease

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future
Kee-Huat Chuah, Wah-Kheong Chan
Clin Mol Hepatol 2023;29(2):401-403.
Published online February 28, 2023
DOI: https://doi.org/10.3350/cmh.2023.0062

Citations

Citations to this article as recorded by  Crossref logo
  • Aerobic Exercise Training Leads to MASH Resolution as Defined by the MASH Resolution Index
    Theja Channapragada, Sarah Batra, Breianna L. Hummer, Vernon M. Chinchilli, Daniel Huang, Rohit Loomba, Ian R. Schreibman, Jonathan G. Stine
    Digestive Diseases and Sciences.2025;[Epub]     CrossRef
  • Development of a machine learning-based model to predict hepatic inflammation in chronic hepatitis B patients with concurrent hepatic steatosis: a cohort study
    Fajuan Rui, Yee Hui Yeo, Liang Xu, Qi Zheng, Xiaoming Xu, Wenjing Ni, Youwen Tan, Qing-Lei Zeng, Zebao He, Xiaorong Tian, Qi Xue, Yuanwang Qiu, Chuanwu Zhu, Weimao Ding, Jian Wang, Rui Huang, Yayun Xu, Yunliang Chen, Junqing Fan, Zhiwen Fan, Xiaolong Qi,
    eClinicalMedicine.2024; 68: 102419.     CrossRef
  • Functional effects and mechanisms of Phyllanthus emblica fruit and gallic acid on metabolic diseases: Experimental evidence and clinical perspectives
    Xiaoling Gou, Yin Ding, Yamei Wu, Yiwen Tao, Yaqian Wang, Yue Wang, Jingye Liu, Mi Ma, Xianhua Zhou, Tsedien Nhamdriel, Gang Fan
    Food Bioscience.2024; 59: 104039.     CrossRef
  • Machine learning based identification potential feature genes for prediction of drug efficacy in nonalcoholic steatohepatitis animal model
    Marwa Matboli, Ibrahim Abdelbaky, Abdelrahman Khaled, Radwa Khaled, Shaimaa Hamady, Laila M. Farid, Mariam B. Abouelkhair, Noha E. El-Attar, Mohamed Farag Fathallah, Manal S. Abd EL Hamid, Gena M. Elmakromy, Marwa Ali
    Lipids in Health and Disease.2024;[Epub]     CrossRef
  • 8,374 View
  • 79 Download
  • 4 Web of Science
  • Crossref

Original Article

Steatotic liver disease

Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort
Yi-Wen Ting, Amanda Shen-Yee Kong, Shamsul Mohd Zain, Wah-Kheong Chan, Hwa-Li Tan, Zahurin Mohamed, Yuh-Fen Pung, Rosmawati Mohamed
Clin Mol Hepatol 2021;27(3):486-498.
Published online February 23, 2021
DOI: https://doi.org/10.3350/cmh.2020.0162
Background/Aims
17β-hydroxysteroid dehydrogenase 13 (HSD17B13) variants were recently reported to have significantly lower odds of non-alcoholic fatty liver disease (NAFLD). This is a two-part study that aimed to evaluate the association of HSD17B13 variants with NAFLD and its histological severity, and to identify the association of the variants with clinical outcomes in a cohort of biopsy-proven NAFLD patients.
Methods
Consecutive biopsy-proven NAFLD patients and controls without fatty liver were recruited for this study between 2009 and 2014. Genotyping for HSD17B13 variants was performed using rhAmp assays. A total of 165 patients with NAFLD were monitored up until August 2019. Clinical outcomes were recorded.
Result
s: HSD17B13 rs72613567 TA allele and rs6834314 G allele were associated with lower odds of non-alcoholic steatohepatitis (NASH) in the overall cohort and among ethnic Chinese, but not among ethnic Malays or Indians (P<0.05). During a mean follow-up of 89 months, 32 patients (19.4%) experienced at least one clinical outcome (cardiovascular events, n=22; liver-related complications, n=6; extra-hepatic malignancy, n=5; and mortality, n=6). The rs72613567 homozygous TA allele and the rs6834314 homozygous G allele were independently associated with a lower incidence of liver-related complications (hazard ratio [HR], 0.004; 95% confidence interval [CI], 0.00–0.64; P=0.033 and HR, 0.01; 95% CI, 0.00–0.97; P=0.048, respectively) and were associated with lower grade of hepatocyte ballooning among the ethnic Chinese.
Conclusion
HSD17B13 rs72613567 and rs6834314 variants were inversely associated with NAFLD and NASH, and were associated with lower incidence of adverse liver outcomes in a cohort of multi-ethnic Asian patients with NAFLD.

Citations

Citations to this article as recorded by  Crossref logo
  • RNA-based drugs: current, imminent and possible therapeutic applications
    Sebastiano A. Torrisi, Federica Geraci, Lidia Diolosà, Angelina De Luca, Luca Falzone, Filippo Drago, Massimo Libra, Gian Marco Leggio
    Pharmacology & Therapeutics.2026; 277: 108958.     CrossRef
  • Ethnic differences in metabolic and histologic features among White, Hispanic, Black and Asian patients with metabolic-associated Steatotic liver disease: A network meta-analysis
    Limin Lin, Jiaming Lai, Ling Luo, Junzhao Ye, Bihui Zhong
    Annals of Hepatology.2025; 30(2): 101780.     CrossRef
  • Unraveling Mechanisms of Genetic Risks in Metabolic Dysfunction–Associated Steatotic Liver Diseases: A Pathway to Precision Medicine
    Xiang Zhang, Kyong-Mi Chang, Jun Yu, Rohit Loomba
    Annual Review of Pathology: Mechanisms of Disease .2025; 20(1): 375.     CrossRef
  • Role of genetic variants and DNA methylation of lipid metabolism-related genes in metabolic dysfunction-associated steatotic liver disease
    Jun-Jie Wang, Xiao-Yuan Chen, Yi-Rong Zhang, Yan Shen, Meng-Lin Zhu, Jun Zhang, Jun-Jie Zhang
    Frontiers in Physiology.2025;[Epub]     CrossRef
  • Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease
    Mohammad Shafi Kuchay, Narendra Singh Choudhary, Bruno Ramos-Molina
    American Journal of Physiology-Cell Physiology.2025; 328(5): C1637.     CrossRef
  • Meta‐Analysis: Effects of Steatotic Liver Disease‐Associated Genetic Risk Alleles on Longitudinal Outcomes
    Matthew Kubina, Vitchapong Prasitsumrit, Jarell Tan, Joo Wei Ethan Quek, Dhiraj Peddu, Ankit Mishra, Pojsakorn Danpanichkul, Jake P. Mann, Eric Trépo, Stephan Buch, Daniel Q. Huang, Cheng Han Ng, Mark D. Muthiah, Yu Jun Wong, Karn Wijarnpreecha, Vincent L
    Alimentary Pharmacology & Therapeutics.2025; 62(3): 244.     CrossRef
  • Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis
    Arun J. Sanyal, Jorg Taubel, Prajakta Badri, Sarah Bond, Nune Makarova, Weizhi Zhao, Swati Duggal, Farshad Kajbaf, Benjamin A. Olenchock, John M. Gansner
    Journal of Hepatology.2025; 83(4): 838.     CrossRef
  • The Distribution and Survival Association of Genetic Polymorphisms in Thai Patients with Hepatocellular Carcinoma According to Underlying Liver Disease
    Theint Cho Zin Aung, Bootsakorn Boonkaew, Maneerat Chayanupatkul, Kittiyod Poovorawan, Natthaya Chuaypen, Pisit Tangkijvanich
    Genes.2025; 16(7): 808.     CrossRef
  • Metabolic and genetic mechanisms of metabolic dysfunction-associated steatotic liver disease: an integrative perspective from molecular pathways to clinical challenges
    Jingyuan Ma, Yanna Ma, Xing Wan, Junchen Li, Yunshu Zhang, Jifeng Liu, Yunhai Gao
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • 17-Beta-Hydroxysteroid Dehydrogenase 13 Loss of Function Does Not Confer Protection to Nonalcoholic Fatty Liver Disease in Indian Population
    Bale Govardhan, V. Kulkarni Anand, Padaki Nagaraja Rao, P. Balachandran Menon, Sharma Mithun, Mitnala Sasikala, T.R. Sowmya, Sekaran Anuradha, C. Pawar Smita, D. Nageshwar Reddy, Vishnubhotla Ravikanth
    Journal of Clinical and Experimental Hepatology.2024; 14(4): 101371.     CrossRef
  • GLP-1 receptor agonists in the treatment of diabetic non–alcoholic steatohepatitis patients
    Ernest A. Adeghate
    Expert Opinion on Pharmacotherapy.2024; 25(3): 223.     CrossRef
  • Emerging roles of RNA‐binding proteins in fatty liver disease
    Oluwafolajimi Adesanya, Diptatanu Das, Auinash Kalsotra
    WIREs RNA.2024;[Epub]     CrossRef
  • Are we ready for genetic testing in metabolic dysfunction‐associated steatotic liver disease?
    Adele Tulone, Grazia Pennisi, Carlo Ciccioli, Giuseppe Infantino, Claudia La Mantia, Roberto Cannella, Francesco Mercurio, Salvatore Petta
    United European Gastroenterology Journal.2024; 12(5): 638.     CrossRef
  • Genetic predisposition to metabolic dysfunction-associated fatty liver disease
    O.E. Abaturov, A.O. Nikulina
    CHILD`S HEALTH.2024; 19(3): 162.     CrossRef
  • Interaction Between PNPLA3 and SIRT5 Genetic Variants in Association with Liver Fibrosis Severity in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease
    Kamonchanok Moonlisarn, Pornjira Somnark, Bootsakorn Boonkaew, Chalermarat Bunchorntavakul, Pisit Tangkijvanich
    Genes.2024; 15(11): 1370.     CrossRef
  • Non-alcoholic fatty liver disease establishment and progression: genetics and epigenetics as relevant modulators of the pathology
    Camila Cristiane Pansa, Letícia Ramos Molica, Karen C. M. Moraes
    Scandinavian Journal of Gastroenterology.2023; 58(5): 521.     CrossRef
  • Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD
    Maral Amangurbanova, Daniel Q. Huang, Rohit Loomba
    Alimentary Pharmacology & Therapeutics.2023; 57(1): 37.     CrossRef
  • Geographical similarity and differences in the burden and genetic predisposition of NAFLD
    Terry Cheuk‐Fung Yip, Eduardo Vilar‐Gomez, Salvatore Petta, Yusuf Yilmaz, Grace Lai‐Hung Wong, Leon A. Adams, Victor de Lédinghen, Silvia Sookoian, Vincent Wai‐Sun Wong
    Hepatology.2023; 77(4): 1404.     CrossRef
  • Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”
    Seung Min Lee, Dae Won Jun
    Clinical and Molecular Hepatology.2023; 29(1): 171.     CrossRef
  • Discovery of a Novel Potent and Selective HSD17B13 Inhibitor, BI-3231, a Well-Characterized Chemical Probe Available for Open Science
    Sven Thamm, Marina K. Willwacher, Gary E. Aspnes, Tom Bretschneider, Nicholas F. Brown, Silke Buschbom-Helmke, Thomas Fox, Emanuele M. Gargano, Daniel Grabowski, Christoph Hoenke, Damian Matera, Katja Mueck, Stefan Peters, Sophia Reindl, Doris Riether, Ma
    Journal of Medicinal Chemistry.2023; 66(4): 2832.     CrossRef
  • Comparison between obese and non-obese nonalcoholic fatty liver disease
    Wah-Kheong Chan
    Clinical and Molecular Hepatology.2023; 29(Suppl): S58.     CrossRef
  • Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI‐PDFF in NAFLD
    Beom K. Kim, Nicole Bernstein, Daniel Q. Huang, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi Nakajim
    Alimentary Pharmacology & Therapeutics.2023; 58(2): 229.     CrossRef
  • Polymorphisms of HSD17B13, GCKR, HFE, and CP as factors of the development of non-alcoholic fatty liver disease and comorbid diseases
    O. V. Smirnova, D. V. Lagutinskaya
    Meditsinskiy sovet = Medical Council.2023; (8): 119.     CrossRef
  • Food Network Analysis in Non-Obese Patients with or without Steatosis
    Rossella Donghia, Pasqua Letizia Pesole, Sergio Coletta, Caterina Bonfiglio, Giovanni De Pergola, Sara De Nucci, Roberta Rinaldi, Gianluigi Giannelli
    Nutrients.2023; 15(12): 2713.     CrossRef
  • Associations between genetic variants of HSD17B13 and fasting plasma glucose in Chinese children
    Ping-ping Zhang, Jie-yun Song, Li Li, Miao Xu, Hui Wang, Hai-jun Wang
    Nutrition, Metabolism and Cardiovascular Diseases.2023; 33(9): 1778.     CrossRef
  • Advances in genetic variation in metabolism-related fatty liver disease
    Fan Shi, Mei Zhao, Shudan Zheng, Lihong Zheng, Haiqiang Wang
    Frontiers in Genetics.2023;[Epub]     CrossRef
  • Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches
    Eirini Martinou, Marinos Pericleous, Irena Stefanova, Vasha Kaur, Angeliki M. Angelidi
    Diagnostics.2022; 12(2): 407.     CrossRef
  • Therapeutic RNA-silencing oligonucleotides in metabolic diseases
    Algera Goga, Markus Stoffel
    Nature Reviews Drug Discovery.2022; 21(6): 417.     CrossRef
  • Impact of a Loss-of-Function Variant in HSD17B13 on Hepatic Decompensation and Mortality in Cirrhotic Patients
    Antonio Gil-Gómez, Ángela Rojas, María R. García-Lozano, Rocío Muñoz-Hernández, Rocío Gallego-Durán, Douglas Maya-Miles, Rocío Montero-Vallejo, Sheila Gato, Javier Gallego, Rubén Francés, Germán Soriano, Javier Ampuero, Manuel Romero-Gómez
    International Journal of Molecular Sciences.2022; 23(19): 11840.     CrossRef
  • Update on genetics and epigenetics in metabolic associated fatty liver disease
    Xiaopeng Zhu, Mingfeng Xia, Xin Gao
    Therapeutic Advances in Endocrinology and Metabolism.2022;[Epub]     CrossRef
  • No evidence for a causal link between Helicobacter pylori infection and nonalcoholic fatty liver disease: A bidirectional Mendelian randomization study
    Yuwei Liu, Hongqin Xu, ZiHan Zhao, Yutong Dong, Xiaomei Wang, Junqi Niu
    Frontiers in Microbiology.2022;[Epub]     CrossRef
  • Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis
    Shan Tang, Jing Zhang, Ting-Ting Mei, Wen-Yan Zhang, Su-Jun Zheng, Hai-Bin Yu
    BMC Gastroenterology.2021;[Epub]     CrossRef
  • An analysis of polygenic risk scores for non-alcoholic fatty liver disease
    Dae Won Jun
    Clinical and Molecular Hepatology.2021; 27(3): 446.     CrossRef
  • 11,670 View
  • 283 Download
  • 32 Web of Science
  • Crossref

Review

Benign liver tumors and cystic disease of liver

Benign hepatocellular nodules of healthy liver: focal nodular hyperplasia and hepatocellular adenoma
Massimo Roncalli, Amedeo Sciarra, Luca Di Tommaso
Clin Mol Hepatol 2016;22(2):199-211.
Published online May 18, 2016
DOI: https://doi.org/10.3350/cmh.2016.0101
Owing to the progress of imaging techniques, benign hepatocellular nodules are increasingly discovered in the clinical practice. This group of lesions mostly arises in the context of a putatively normal healthy liver and includes either pseudotumoral and tumoral nodules. Focal nodular hyperplasia and hepatocellular adenoma are prototypical examples of these two categories of nodules. In this review we aim to report the main pathological criteria of differential diagnosis between focal nodular hyperplasia and hepatocellular adenoma, which mainly rests upon morphological and phenotypical features. We also emphasize that for a correct diagnosis the clinical context such as sex, age, assumption of oral contraceptives, associated metabolic or vascular disturbances is of paramount importance. While focal nodular hyperplasia is a single entity epidemiologically more frequent than adenoma, the latter is representative of a more heterogeneous group which has been recently and extensively characterized from a clinical, morphological, phenotypical and molecular profile. The use of the liver biopsy in addition to imaging and the clinical context are important diagnostic tools of these lesions. In this review we will survey their systematic pathobiology and propose a diagnostic algorithm helpful to increase the diagnostic accuracy of not dedicated liver pathologists. The differential diagnosis between so-called typical and atypical adenoma and well differentiated hepatocellular carcinoma will also be discussed.

Citations

Citations to this article as recorded by  Crossref logo
  • Burden of Liver Disease Among Individuals With Turner Syndrome and Klinefelter Syndrome: A Comprehensive Perspective
    Mohamad Jamalinia, Amedeo Lonardo, Ralf Weiskirchen
    Chronic Diseases and Translational Medicine.2026;[Epub]     CrossRef
  • PET/MRI evaluation of hepatobiliary tumors
    Joseph FRANKL, Naveen RAJAMOHAN, Jaewon YANG, Robert C. SIBLEY
    The Quarterly Journal of Nuclear Medicine and Molecular Imaging.2025;[Epub]     CrossRef
  • Diagnosis and Management of Benign Liver Tumors
    Yeonjung Ha
    The Korean Journal of Gastroenterology.2025; 85(3): 314.     CrossRef
  • Hepatocellular adenomas
    Hans-Christian Pommergaard, Henning Grønbæk, Eva Fallentin, Nikolaj Skou, Nicolai Aagaard Schultz, Mette Bak Nielsen, Gro Linno Willemoe
    Ugeskrift for Læger.2025; : 1.     CrossRef
  • Focal Hyperechoic Hepatic Lesions in Northern Region of Saudi Arabia: Prevalence, Radiologic Features, and Clinical Relevance
    Fatimah M. Alonzi, Mohammed J. Alsaadi, Khaled Said Karam, Essa M. Alanzi, Noura K. Alhathal, Maram F. Alreshidi, Abdulrahman M. Alfuraih
    Journal of Clinical Medicine.2025; 14(19): 6987.     CrossRef
  • Focal nodular hyperplasia combined with hepatocellular carcinoma with bone metastasis: a case report and literature review
    Yuliang Zhang, Xiyue Deng, Kaiyue Cao, Yang Li
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Variation in the management of benign liver tumors: A European survey and case vignette study
    Martijn P.D. Haring, Robbert J. de Haas, Frederike G.I. van Vilsteren, Joost M. Klaase, Evelien W. Duiker, Hans Blokzijl, Koert P. de Jong, Vincent E. de Meijer, Frans J.C. Cuperus, Y.S. de Boer, R.A. de Man, C.M. den Hoed, J.P.H. Drenth, M.G. Garcovich,
    Clinics and Research in Hepatology and Gastroenterology.2023; 47(3): 102094.     CrossRef
  • Hepatocellular Neoplasm of Uncertain Potential of Malignancy or Well-Differentiated Hepatocellular Carcinoma Arising within Hepatocellular Adenoma
    Elisabete Campos, Roberto Silva, Sara Rodrigues, Marinho de Almeida, Joanne Lopes, Marisa Aral, Humberto Cristino, Luís Graça, Elisabete Barbosa, Neil Donald Merrett
    Case Reports in Surgery.2023; 2023: 1.     CrossRef
  • Desmoplastic small round cell tumor of the liver: diagnosing a rare case on liver biopsy
    Xiao Feng, Jing Tao, Qiang Zhou, Yi-Dan Qiao, Le-Jian He, Nan Zhang
    Diagnostic Pathology.2023;[Epub]     CrossRef
  • Pedunculated Focal Nodular Hyperplasia: When in Doubt, Should We Cut It Out?
    Christos Tsalikidis, Athanasia Mitsala, George Pappas-Gogos, Konstantinos Romanidis, Alexandra K. Tsaroucha, Michail Pitiakoudis
    Journal of Clinical Medicine.2023; 12(18): 6034.     CrossRef
  • Significance of hepatocyte atypia in liver fine needle aspiration
    Susan Shyu, Syed Z. Ali
    Diagnostic Cytopathology.2022; 50(4): 186.     CrossRef
  • Senescence markers in focal nodular hyperplasia of the liver: pathogenic considerations on the basis of immunohistochemical results
    Helmut Denk, Daniela Pabst, Peter M. Abuja, Robert Reihs, Brigitte Tessaro, Kurt Zatloukal, Carolin Lackner
    Modern Pathology.2022; 35(1): 87.     CrossRef
  • Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice
    Elvire Desjonqueres, Claudia Campani, Fabio Marra, Jessica Zucman‐Rossi, Jean‐Charles Nault
    Liver International.2022; 42(3): 492.     CrossRef
  • Genomic analysis of focal nodular hyperplasia with associated hepatocellular carcinoma unveils its malignant potential: a case report
    Caner Ercan, Mairene Coto-Llerena, John Gallon, Lana Fourie, Mattia Marinucci, Gabriel F. Hess, Jürg Vosbeck, Stephanie Taha-Mehlitz, Tuyana Boldanova, Marie-Anne Meier, Alexandar Tzankov, Matthias S. Matter, Martin H. K. Hoffmann, Luca Di Tommaso, Markus
    Communications Medicine.2022;[Epub]     CrossRef
  • Comparison of the Value of Color Doppler Ultrasound and Multislice Spiral CT in the Differential Diagnosis of Benign and Malignant Nodules in the Liver
    Peiwan Jia, Ruirong Liu, Yun Liu, Yanyan Wu, Ting Dou, Yuvaraja Teekaraman
    Contrast Media & Molecular Imaging.2022;[Epub]     CrossRef
  • Magnetic Resonance Imaging Findings of an Intrahepatic Bile Duct Adenoma: A Case Report
    Jie Yuan, Kun Liu, Mengxiao Liu, Songhua Zhan
    Cureus.2022;[Epub]     CrossRef
  • Liver Abnormalities in Turner Syndrome: The Importance of Estrogen Replacement
    Istvan Fedor, Eva Zold, Zsolt Barta
    Journal of the Endocrine Society.2022;[Epub]     CrossRef
  • Microvascular imaging: new Doppler technology for assessing focal liver lesions. Is it useful?
    A. Wilson, A.K.P. Lim
    Clinical Radiology.2022; 77(12): e807.     CrossRef
  • A focalis nodularis hyperplasia multimodális kezelése
    Damján Pekli, Bálint Kokas, Dávid Bárdos, András Fülöp, Péter Pajor, Oszkár Hahn, Ildikó Illyés, Attila Kovács, Attila Szijártó
    Orvosi Hetilap.2022; 163(15): 606.     CrossRef
  • CT-Based Radiomics Nomogram: A Potential Tool for Differentiating Hepatocellular Adenoma From Hepatocellular Carcinoma in the Noncirrhotic Liver
    Pei Nie, Ning Wang, Jing Pang, Guangjie Yang, Shaofeng Duan, Jingjing Chen, Wenjian Xu
    Academic Radiology.2021; 28(6): 799.     CrossRef
  • Panel of potential lncRNA biomarkers can distinguish various types of liver malignant and benign tumors
    Olga Y. Burenina, Natalia L. Lazarevich, Inna F. Kustova, Daria A. Shavochkina, Ekaterina A. Moroz, Nikolay E. Kudashkin, Yuriy I. Patyutko, Alexey V. Metelin, Eduard F. Kim, Dmitry A. Skvortsov, Timofei S. Zatsepin, Maria P. Rubtsova, Olga A. Dontsova
    Journal of Cancer Research and Clinical Oncology.2021; 147(1): 49.     CrossRef
  • Benign hepatocellular lesions and neoplasms: a comprehensive review
    Luiz Paulo Guido, Monica T. Garcia-Buitrago
    Diagnostic Histopathology.2021; 27(2): 85.     CrossRef
  • Hepatocellular adenomas: recent updates
    Haeryoung Kim, Young Nyun Park
    Journal of Pathology and Translational Medicine.2021; 55(3): 171.     CrossRef
  • Appearance of Focal Nodular Hyperplasia after Chemotherapy in Two Patients during Follow-Up of Colon Carcinoma
    L. A. de Wert, S. A. Huisman, F. Imani, D. J. de Gooyer, J. M. G. H. van Riel, P. D. Gobardhan, A. M. Rijken, Mario Ganau
    Case Reports in Surgery.2021; 2021: 1.     CrossRef
  • Scoping review of clinical practice guidelines on the management of benign liver tumours
    Martijn P D Haring, Frans J C Cuperus, Evelien W Duiker, Robbert J de Haas, Vincent E de Meijer
    BMJ Open Gastroenterology.2021; 8(1): e000592.     CrossRef
  • Diagnosis and surgical treatment of a rare hepatic angiomyolipoma with internal hemorrhage
    Mizelle D'Silva, Hee Young Na, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Jun Suh Lee, Boram Lee, Moonhwan Kim
    Annals of Hepato-Biliary-Pancreatic Surgery.2021; 25(4): 532.     CrossRef
  • Alpha‐fetoprotein and focal nodular hyperplasia: An unconventional couple
    Paul Carrier, Anne Guyot, Marilyne Debette‐Gratien, Fabien Fredon, Marie‐Pierre Teissier, François Labrousse, Véronique Loustaud‐Ratti
    JGH Open.2021; 5(11): 1316.     CrossRef
  • Hepatobiliary MR contrast agents are useful to diagnose hepatocellular carcinoma in patients with Budd-Chiari syndrome
    Morgane Van Wettere, Luisa Paulatto, Lucas Raynaud, Onorina Bruno, Audrey Payancé, Aurélie Plessier, Pierre-Emmanuel Rautou, Valérie Paradis, Dominique Cazals-Hatem, Dominique Valla, Valérie Vilgrain, Maxime Ronot
    JHEP Reports.2020; 2(3): 100097.     CrossRef
  • Patterns of enhancement in the hepatobiliary phase of gadoxetic acid-enhanced MRI
    Cathryn L Hui, Marcela Mautone
    The British Journal of Radiology.2020;[Epub]     CrossRef
  • Focal Nodular Hyperplasia and Hepatic Adenoma
    Lauren Myers, Joseph Ahn
    Clinics in Liver Disease.2020; 24(3): 389.     CrossRef
  • OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd‐EOB‐DTPA uptake and correlates with risk of malignancy
    Amedeo Sciarra, Sabine Schmidt, Alessandro Pellegrinelli, Marco Maggioni, Daniele Dondossola, Jerome Pasquier, Claudia Cigala, Delfina Tosi, Nermin Halkic, Gaetano Bulfamante, Giuseppe Viale, Silvano Bosari, Charles Balabaud, Paulette Bioulac‐Sage, Christ
    Liver International.2019; 39(1): 158.     CrossRef
  • MicroRNA Expression in Focal Nodular Hyperplasia in Comparison with Cirrhosis and Hepatocellular Carcinoma
    Gábor Lendvai, Tímea Szekerczés, Benedek Gyöngyösi, Krisztina Schlachter, Endre Kontsek, Adrián Pesti, Attila Patonai, Klára Werling, Ilona Kovalszky, Zsuzsa Schaff, András Kiss
    Pathology & Oncology Research.2019; 25(3): 1103.     CrossRef
  • Challenging liver lesions in noncirrhotic patients: Report of three cases
    Tania Franceschini, Deborah Malvi, Lorenzo Maroni, Matteo Ravaioli, Matteo Cescon, Antonia D’Errico, Francesco Vasuri
    Therapeutic Advances in Gastrointestinal Endoscopy.2019;[Epub]     CrossRef
  • Down-regulation of cell membrane localized NTCP expression in proliferating hepatocytes prevents hepatitis B virus infection
    Ying Yan, Lena Allweiss, Danli Yang, Jingting Kang, Jianwen Wang, Xiangjun Qian, Ting Zhang, Hui Liu, Lu Wang, Shuhong Liu, Jianhua Sui, Xiangmei Chen, Maura Dandri, Jingmin Zhao, Fengmin Lu
    Emerging Microbes & Infections.2019; 8(1): 879.     CrossRef
  • Multi-parameter ultrasound based on the logistic regression model in the differential diagnosis of hepatocellular adenoma and focal nodular hyperplasia
    Meng Wu, Ru-Hai Zhou, Feng Xu, Xian-Peng Li, Ping Zhao, Rui Yuan, Yu-Peng Lan, Wei-Xia Zhou
    World Journal of Gastrointestinal Oncology.2019; 11(12): 1193.     CrossRef
  • Focal Nodular Hyperplasia in a Young Male as an Incidental Finding Associated With Acute Lithiasic Chronic Cholecystitis. Case Report and Literature Review
    José J. Gómez-Ramos, María G. Ascencio-Rodríguez, Alejandro Marín-Medina, Moises Alejandro Alatorre Jimenez, Vickramjeet Johal, Eduardo Esteban-Zubero
    Iberoamerican Journal of Medicine.2019; 1(1): 16.     CrossRef
  • Primary Liver Cancers—Part 1
    Kun Jiang, Sameer Al-Diffalha, Barbara A. Centeno
    Cancer Control.2018;[Epub]     CrossRef
  • Characterization of hepatocellular adenoma and carcinoma using microRNA profiling and targeted gene sequencing
    Jian Zheng, Eran Sadot, Joana A. Vigidal, David S. Klimstra, Vinod P. Balachandran, T. Peter Kingham, Peter J. Allen, Michael I. D’Angelica, Ronald P. DeMatteo, William R. Jarnagin, Andrea Ventura, Yu-Jia Chang
    PLOS ONE.2018; 13(7): e0200776.     CrossRef
  • Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma
    Archana Rastogi
    World Journal of Gastroenterology.2018; 24(35): 4000.     CrossRef
  • A practical diagnostic approach to hepatic masses
    Monika Vyas, Dhanpat Jain
    Indian Journal of Pathology and Microbiology.2018; 61(1): 2.     CrossRef
  • Hepatocellular adenoma: Classification, variants and clinical relevance
    Paulette Bioulac-Sage, Christine Sempoux, Charles Balabaud
    Seminars in Diagnostic Pathology.2017; 34(2): 112.     CrossRef
  • Tissue Biomarkers in Hepatocellular Tumors: Which, When, and How
    Luca Di Tommaso, Massimo Roncalli
    Frontiers in Medicine.2017;[Epub]     CrossRef
  • Comparison of Subtypes of Hepatocellular Adenoma to Hepatocellular Carcinoma and Non-Neoplastic Liver Tissue in Terms of PTEN Expression
    Grzegorz Szparecki, T. Ilczuk, N. Gabzdyl, B. Górnicka
    Folia Biologica.2017; 63(5-6): 202.     CrossRef
  • Leberadenome und andere maligne und benigne Lebertumoren
    F. Hartmann, A. Tannapfel
    Der Gastroenterologe.2016; 11(5): 359.     CrossRef
  • 25,276 View
  • 643 Download
  • 44 Web of Science
  • Crossref

Case Reports

Benign liver tumors and cystic disease of liver

A case of focal nodular hyperplasia with growth progression during pregnancy
Min Ji Kim, Sang Young Han, Yang Hyun Baek, Sung Wook Lee, Hee Jin Kwon
Clin Mol Hepatol 2014;20(4):392-397.
Published online December 24, 2014
DOI: https://doi.org/10.3350/cmh.2014.20.4.392

Focal nodular hyperplasia (FNH) is the second most common benign solid tumor of the liver and is usually found in young females. In FNH, spontaneous bleeding or rupture rarely occurs and malignant transformation is unlikely. The etiology of FNH is unclear, but because of female predominance and young age at onset, it seems that female hormone has an important role for the development of FNH. Although the development and the complications of hepatocellular adenomas have been related to the use of oral contraceptives and pregnancy, the influence of oral contraceptives and pregnancy on the growth and complications of FNH is controversial. Most FNH are stable in size and rarely complicated during pregnancy. We describe here a case of FNH with growth progression during pregnancy in a 27-year-old female. Her course of pregnancy and delivery was uneventful. Two months after delivery, the size of FNH was decreased.

Citations

Citations to this article as recorded by  Crossref logo
  • Arterial embolization of focal nodular hyperplasia of the liver: A case report
    Hiba Ben Hassine, Mohamed Ali Chaouch, Maissa Jallali, Hanen Zenati, Besma Gafsi, Faouzi Noomen
    International Journal of Surgery Case Reports.2024; 116: 109473.     CrossRef
  • Imaging strategy for focal nodular hyperplasia in children: long-term experience from two specialist European centres
    Greg Chambers, Angelo Zarfati, Tobi Aderotimi, Sophie Branchereau, Terry Humphrey, Helen Woodley, Stéphanie Franchi-Abella
    Pediatric Radiology.2023; 53(1): 46.     CrossRef
  • Large focal nodular hyperplasia of the liver treated with transcatheter arterial embolization and laparoscopic resection: A case report
    Hiroki Sato, Kazuteru Monden, Toshimitsu Iwasaki, Masayoshi Hioki, Hiroshi Sadamori, Norihisa Takakura
    Asian Journal of Endoscopic Surgery.2023; 16(3): 579.     CrossRef
  • Pedunculated Focal Nodular Hyperplasia: When in Doubt, Should We Cut It Out?
    Christos Tsalikidis, Athanasia Mitsala, George Pappas-Gogos, Konstantinos Romanidis, Alexandra K. Tsaroucha, Michail Pitiakoudis
    Journal of Clinical Medicine.2023; 12(18): 6034.     CrossRef
  • Estrogen-Driven Growth of Focal Nodular Hyperplasia: Truth or Myth?
    Ashraf A. Ashhab, Ahmad Abu-Sulb, Ju Dong Yang, Mazen Noureddin, Vinay Sundaram, Alexander Kuo, Walid S. Ayoub
    ACG Case Reports Journal.2021; 8(1): e00531.     CrossRef
  • Management of focal nodular hyperplasia of the liver: Experience of 50 pediatric patients in a tertiary center
    Angelo Zarfati, Greg Chambers, Luca Pio, Florent Guerin, Virginie Fouquet, Stéphanie Franchi-Abella, Sophie Branchereau
    Journal of Pediatric Surgery.2020; 55(9): 1885.     CrossRef
  • Uncommon evolutions and complications of common benign liver lesions
    Federica Vernuccio, Maxime Ronot, Marco Dioguardi Burgio, Jérôme Lebigot, Wassim Allaham, Christophe Aubé, Giuseppe Brancatelli, Valérie Vilgrain
    Abdominal Radiology.2018; 43(8): 2075.     CrossRef
  • 16,314 View
  • 74 Download
  • 9 Web of Science
  • Crossref

Viral hepatitis

Pure red-cell aplasia and autoimmune hemolytic anemia in a patient with acute hepatitis A
Hyo Jeong Chang, Dong Hyun Sinn, Sung Gyun Cho, Tae Hoon Oh, Tae Joo Jeon, Won Chang Shin, Won Choong Choi
Clin Mol Hepatol 2014;20(2):204-207.
Published online June 30, 2014
DOI: https://doi.org/10.3350/cmh.2014.20.2.204

Pure red cell aplasia (PRCA) and autoimmune hemolytic anemia (AIHA) have rarely been reported as an extrahepatic manifestation of acute hepatitis A (AHA). We report herein a case of AHA complicated by both PRCA and AIHA. A 49-year-old female with a diagnosis of AHA presented with severe anemia (hemoglobin level, 6.9 g/dL) during her clinical course. A diagnostic workup revealed AIHA and PRCA as the cause of the anemia. The patient was treated with an initial transfusion and corticosteroid therapy. Her anemia and liver function test were completely recovered by 9 months after the initial presentation. We review the clinical features and therapeutic strategies for this rare case of extrahepatic manifestation of AHA.

Citations

Citations to this article as recorded by  Crossref logo
  • Case Report: Acute hepatitis A virus infection presenting with direct antiglobulin test-negative autoimmune hemolytic anemia and α-thalassemia trait
    Habiba Debbabi, Eya Chakroun, Hajer Hassine, Hela Kchir, Dhouha Cherif, Haythem Yacoub, Nadia Maamouri
    F1000Research.2025; 13: 1224.     CrossRef
  • Case Report: Acute hepatitis A virus infection presenting with direct antiglobulin test-negative autoimmune hemolytic anemia and α-thalassemia trait
    Habiba Debbabi, Eya Chakroun, Hajer Hassine, Hela Kchir, Dhouha Cherif, Haythem Yacoub, Nadia Maamouri
    F1000Research.2024; 13: 1224.     CrossRef
  • Exacerbation of autoimmune hemolytic anemia associated with pure red cell aplasia after COVID-19: A case report
    Hideo Kimura, Miki Furukawa, Yutaka Shiga, Tatsuyuki Kai, Ikkoh Yasuda, Shungo Katoh, Eiichiro Sando
    Journal of Infection and Chemotherapy.2023; 29(8): 787.     CrossRef
  • Local and systemic autoimmune manifestations linked to hepatitis A infection
    M Doulberis, A Papaefthymiou, S.A. Polyzos, E Vardaka, M Tzitiridou-Chatzopoulou, D Chatzopoulos, A Koffas, V Papadopoulos, F Kyrailidi, J Kountouras
    Acta Gastro Enterologica Belgica.2023; 86(3): 429.     CrossRef
  • Pure red cell aplasia accompanied by COVID-19 successfully treated using cyclosporine
    Susumu Yamazaki, Erika Naito, Ryu Sekiya, Sanehiro Yogi, Kenichiro Komiyama, Yoshitaka Miyakawa, Makoto Nagata
    Journal of Infection and Chemotherapy.2022; 28(2): 304.     CrossRef
  • Hemolytic Anemia after Acute Hepatitis B Virus Infection: A Case Report and Systematic Review
    Takahiro Suzuki, Takeshi Okamoto, Fujimi Kawai, Shuhei Okuyama, Katsuyuki Fukuda
    Internal Medicine.2022; 61(4): 481.     CrossRef
  • Hepatitis A virus infection is complicated by both pancytopenia and autoimmune hemolytic anemia (AIHA)
    Omar Al jandale, Heba Jumah, Hasan Jamil
    Annals of Medicine and Surgery.2022; 78: 103765.     CrossRef
  • Diagnosis and Management of Autoimmune Hemolytic Anemia in Patients with Liver and Bowel Disorders
    Cristiana Bianco, Elena Coluccio, Daniele Prati, Luca Valenti
    Journal of Clinical Medicine.2021; 10(3): 423.     CrossRef
  • Coombs-negative Autoimmune Hemolytic Anemia Followed by Anti-erythropoetin Receptor Antibody-associated Pure Red Cell Aplasia: A Case Report and Review of Literature
    Mayumi Yoshimi, Yutaka Kadowaki, Yuji Kikuchi, Tsuyoshi Takahashi
    Internal Medicine.2016; 55(5): 511.     CrossRef
  • Pure Red Cell Aplasia and Autoimmune Hemolytic Anemia Sequentially Occurring in a Patient with Large Granular T-lymphocytic Leukemia
    Xuemei Qin, Yuan Yu, Shuxin Yan, Ran Wang, Xinguang Liu, Chunyan Chen
    Internal Medicine.2016; 55(11): 1491.     CrossRef
  • 12,111 View
  • 126 Download
  • 8 Web of Science
  • Crossref

Reviews

Liver fibrosis, cirrhosis, and portal hypertension

Management of portal hypertensive gastropathy and other bleeding
Woo Jin Chung
Clin Mol Hepatol 2014;20(1):1-5.
Published online March 26, 2014
DOI: https://doi.org/10.3350/cmh.2014.20.1.1

A major cause of cirrhosis related morbidity and mortality is the development of variceal bleeding, a direct consequence of portal hypertension. Less common causes of gastrointestinal bleeding are peptic ulcers, malignancy, angiodysplasia, etc. Upper gastrointestinal bleeding has been classified according to the presence of a variceal or non-variceal bleeding. Although non-variceal gastrointestinal bleeding is not common in cirrhotic patients, gastroduodenal ulcers may develop as often as non-cirrhotic patients. Ulcers in cirrhotic patients may be more severe and less frequently associated with chronic intake of non-steroidal anti-inflammatory drugs, and may require more frequently endoscopic treatment. Portal hypertensive gastropathy (PHG) refers to changes in the mucosa of the stomach in patients with portal hypertension. Patients with portal hypertension may experience bleeding from the stomach, and pharmacologic or radiologic interventional procedure may be useful in preventing re-bleeding from PHG. Gastric antral vascular ectasia (GAVE) seems to be different disease entity from PHG, and endoscopic ablation can be the first-line treatment.

Citations

Citations to this article as recorded by  Crossref logo
  • Organ cross-talk: molecular mechanisms, biological functions, and therapeutic interventions for diseases
    Huiting Che, Yidan Gao, Yonghu Xu, Hui Xu, Roland Eils, Mei Tian
    Signal Transduction and Targeted Therapy.2026;[Epub]     CrossRef
  • Helicobacter pylori Infection in Cirrhotic Patients With Portal Hypertensive Gastropathy: A New Enigma?
    Sumaiah J. Alarfaj, Sally Abdallah Mostafa, Ramy A. Abdelsalam, Walaa A. Negm, Thanaa A. El-Masry, Ismail A. Hussein, Ahmed Mohamed El Nakib
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • A case of agnogenic intrahepatic arterioportal fistula complicated by gastric ulcer bleeding and progressive portal thrombosis
    Siwei Yang, Tianhao Su, Zhiyuan Zhang, Jianan Yu, Long Jin
    Portal Hypertension & Cirrhosis.2022; 1(1): 82.     CrossRef
  • Association between Severity of Liver Disease, Frequency of Helicobacter pylori Infection, and Degree of Gastric Lesion in Egyptian Patients with Hepatitis B Virus Infection
    Abir O. El Sadik, Elham Ezzat, Moataz M. Sayed, Amal A. Mohamed, Amal A. Elshimy, Mona Nasar, Shereen S. M. Elshaer
    The American Journal of Tropical Medicine and Hygiene.2018; 98(1): 221.     CrossRef
  • Noninvasive clinical predictors of portal hypertensive gastropathy in patients with liver cirrhosis
    Rajesh Mandhwani, Farina M. Hanif, Muhammad Manzoor Ul Haque, Rajesh Kumar Wadhwa, Nasir Hassan Luck, Muhammad Mubarak
    Journal of Translational Internal Medicine.2017; 5(3): 169.     CrossRef
  • 14,237 View
  • 152 Download
  • 9 Web of Science
  • Crossref

Hepatic neoplasm

The MR imaging diagnosis of liver diseases using gadoxetic acid: Emphasis on hepatobiliary phase
Woo Kyoung Jeong, Young Kon Kim, Kyoung Doo Song, Dongil Choi, Hyo Keun Lim
Clin Mol Hepatol 2013;19(4):360-366.
Published online December 28, 2013
DOI: https://doi.org/10.3350/cmh.2013.19.4.360

Hepatocyte specific contrast agents including gadoxetic acid and gadobenate dimeglumine are very useful to diagnose various benign and malignant focal hepatic lesions and even helpful to estimate hepatic functional reservoir. The far delayed phase image referred to as the hepatobiliary phase makes the sensitivity of detection for malignant focal hepatic lesions increased, but specificity of malignant diseases, including hepatocellular carcinoma, metastasis and cholangiocarcinoma, characterization remained to be undetermined.

Citations

Citations to this article as recorded by  Crossref logo
  • Longitudinal T1ρ quantification in chronic hepatitis B: from fibrosis staging to pegylated interferon-α therapeutic response tracking
    Xin-Gui Peng, Yufei Zhao, Zhi Qin, Yang Jiang, Jingyue Dai, Ying Cui
    European Journal of Radiology.2025; 190: 112203.     CrossRef
  • MRI findings of confluent hepatic fibrosis caused by different etiologies
    Dan Yu, Xiao-Hua Li, Xue-Lin He, Xi-Bin Jia, Zhen-Chang Wang, Zheng-Han Yang, A-Hong Ren
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Case Report: Concurrent two adenomatoid tumors of liver
    Lei Bi
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Bildgebung von neuroendokrinen Tumoren des Gastrointestinaltrakts
    R. Ebner, J. Rübenthaler, J. Ricke, G. T. Sheikh, L. M. Unterrainer, C. J. Auernhammer, C. Spitzweg, M. Brendel, C. Schmid-Tannwald, C. C. Cyran
    Die Radiologie.2024; 64(7): 553.     CrossRef
  • PET/MRI for evaluation of patients with pancreatic cancer
    Zoey N. Duncan, David Summerlin, Janelle T. West, Annie T. Packard, Desiree E. Morgan, Samuel J. Galgano
    Abdominal Radiology.2023; 48(12): 3601.     CrossRef
  • Application of Pharmacokinetic Modeling to Characterize Hepatobiliary Disposition of Imaging Agents and Alterations due to Liver Injury in Isolated Perfused Rat Livers
    Angela Jeong, Catherine M. Pastor, Kim L. R. Brouwer
    Pharmaceutical Research.2023; 40(11): 2513.     CrossRef
  • Hepatobiliary phases in magnetic resonance imaging using liver-specific contrast for focal lesions in clinical practice
    Daniel Alvarenga Fernandes, Eduardo Andreazza Dal Lago, Felipe Aguera Oliver, Bruna Melo Coelho Loureiro, Daniel Lahan Martins, Thiago José Penachim, Ricardo Hoelz de Oliveira Barros, José de Arimatéia Batista Araújo Filho, Larissa Bastos Eloy da Costa, Á
    World Journal of Hepatology.2022; 14(7): 1459.     CrossRef
  • Tumor volume measured using MR volumetry as a predictor of prognosis after surgical resection of single hepatocellular carcinoma
    Sun Kyung Jeon, Dong Ho Lee, Juil Park, Kyung-Suk Suh, Nam-Joon Yi, Suk Kyun Hong, Joon Koo Han
    European Journal of Radiology.2021; 144: 109962.     CrossRef
  • MRI-Based Upper Abdominal Organs-at-Risk Atlas for Radiation Oncology
    Jelena Lukovic, Lauren Henke, Cihan Gani, Tae K. Kim, Teodor Stanescu, Ali Hosni, Patricia Lindsay, Beth Erickson, Richard Khor, Cynthia Eccles, Cheng Boon, Mila Donker, Raj Jagavkar, Marlies E. Nowee, William A. Hall, Parag Parikh, Laura A. Dawson
    International Journal of Radiation Oncology*Biology*Physics.2020; 106(4): 743.     CrossRef
  • Metal-Based Complexes as Pharmaceuticals for Molecular Imaging of the Liver
    Julia Greiser, Wolfgang Weigand, Martin Freesmeyer
    Pharmaceuticals.2019; 12(3): 137.     CrossRef
  • Focal Nodular Hyperplasia of the Liver: Contrast‐Enhanced Ultrasonographic Features With Sonazoid
    Jongmee Lee, Woo Kyoung Jeong, Hyo K. Lim, Ah Young Kim
    Journal of Ultrasound in Medicine.2018; 37(6): 1473.     CrossRef
  • Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma
    Ah Yeong Kim, Dong Hyun Sinn, Woo Kyoung Jeong, Young Kon Kim, Tae Wook Kang, Sang Yun Ha, Chul Keun Park, Gyu Seong Choi, Jong Man Kim, Choon Hyuck David Kwon, Jae-Won Joh, Min-Ji Kim, Insuk Sohn, Sin-Ho Jung, Seung Woon Paik, Won Jae Lee
    Journal of Hepatology.2018; 68(6): 1144.     CrossRef
  • Gd-EOB-DTPA-enhanced MRI for quantitative assessment of liver organ damage after partial hepatic ischaemia reperfusion injury: correlation with histology and serum biomarkers of liver cell injury
    Tobias Getzin, Faikah Gueler, Björn Hartleben, Marcel Gutberlet, Anja Thorenz, Rongjun Chen, Martin Meier, Jan Hinrich Bräsen, Thorsten Derlin, Dagmar Hartung, Hannah A. S. Lang, Hermann Haller, Frank Wacker, Song Rong, Katja Hueper
    European Radiology.2018; 28(10): 4455.     CrossRef
  • Liver imaging reporting and data system v2014 categorization of hepatocellular carcinoma on gadoxetic acid‐enhanced MRI: Comparison with multiphasic multidetector computed tomography
    Ijin Joo, Jeong Min Lee, Dong Ho Lee, Su Joa Ahn, Eun Sun Lee, Joon Koo Han
    Journal of Magnetic Resonance Imaging.2017; 45(3): 731.     CrossRef
  • Effect of Gadoxetic Acid on Quantification of Hepatic Steatosis Using Magnetic Resonance Spectroscopy: A Prospective Study
    Ju Won Kim, Sung Mo Kim, Sook Hee Heo, Jin Woong Kim, Sang Soo Shin, Yong Yeon Jeong, Gwang Woo Jeong, Heoung Keun Kang
    Journal of the Korean Society of Radiology.2017; 76(4): 237.     CrossRef
  • Magnetic resonance findings of hepatic epithelioid hemangioendothelioma: emphasis on hepatobiliary phase using Gd-EOB-DTPA
    Jeong Hyun Lee, Woo Kyoung Jeong, Young Kon Kim, Won Jae Lee, Sang Yun Ha, Kyoung Won Kim, Jihun Kim
    Abdominal Radiology.2017; 42(9): 2261.     CrossRef
  • Diagnosis of Hepatocellular Carcinoma with Gadoxetic Acid-Enhanced MRI: 2016 Consensus Recommendations of the Korean Society of Abdominal Radiology

    Korean Journal of Radiology.2017; 18(3): 427.     CrossRef
  • Characterization of small (≤3 cm) hepatic lesions with atypical enhancement feature and hypointensity in hepatobiliary phase of gadoxetic acid-enhanced MRI in cirrhosis
    Seung Kak Shin, Yun Soo Kim, Seung Joon Choi, Young Sup Shim, Dong Hae Jung, Oh Sang Kwon, Duck Joo Choi, Ju Hyun Kim
    Medicine.2017; 96(29): e7278.     CrossRef
  • Quantitative evaluation of Gd-EOB-DTPA uptake in focal liver lesions by using T1 mapping: differences between hepatocellular carcinoma, hepatic focal nodular hyperplasia and cavernous hemangioma
    Zhenpeng Peng, Chang Li, Tao Chan, Huasong Cai, Yanji Luo, Zhi Dong, Zi-Ping Li, Shi-Ting Feng
    Oncotarget.2017; 8(39): 65435.     CrossRef
  • ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents
    E. Neri, M. A. Bali, A. Ba-Ssalamah, P. Boraschi, G. Brancatelli, F. Caseiro Alves, L. Grazioli, T. Helmberger, J. M. Lee, R. Manfredi, L. Martì-Bonmatì, C. Matos, E. M. Merkle, B. Op De Beeck, W. Schima, S. Skehan, V. Vilgrain, C. Zech, C. Bartolozzi
    European Radiology.2016; 26(4): 921.     CrossRef
  • Hepatic enhancement of Gd‐EOB‐DTPA‐enhanced 3 Tesla MR imaging: Assessing severity of liver cirrhosis
    Sunyoung Lee, Dongil Choi, Woo Kyoung Jeong
    Journal of Magnetic Resonance Imaging.2016; 44(5): 1339.     CrossRef
  • Image Findings of Sarcomatous Intrahepatic Cholangiocarcinoma Focused on Gd-EOB-DTPA Enhanced MRI: A Case Report
    Ki Beom Kim, Seong Hoon Kim
    Investigative Magnetic Resonance Imaging.2015; 19(1): 47.     CrossRef
  • CT of Hepatic Sarcoidosis: Small Nodular Lesions Simulating Metastatic Disease
    Duygu Herek
    Polish Journal of Radiology.2015; 80: 178.     CrossRef
  • Diagnosis and treatment of benign liver nodules: Brazilian Society of Hepatology (SBH) recommendations
    Edna Strauss, Adalgisa de Souza Paiva Ferreira, Alex Vianey Callado França, Andre Castro Lyra, Fabio Marinho do Rego Barros, Ivonete Silva, José Huygens Parente Garcia, Edison Roberto Parise
    Arquivos de Gastroenterologia.2015; 52(suppl 1): 47.     CrossRef
  • Focal liver lesions detection and characterization: The advantages of gadoxetic acid-enhanced liver MRI
    Stefano Palmucci
    World Journal of Hepatology.2014; 6(7): 477.     CrossRef
  • 14,448 View
  • 147 Download
  • Crossref

Liver Imaging

Hepatic neoplasm

Pseudocirrhosis as a complication after chemotherapy for hepatic metastasis from breast cancer
Woo Kyoung Jeong, Seo-Youn Choi, Jinoo Kim
Clin Mol Hepatol 2013;19(2):190-194.
Published online June 27, 2013
DOI: https://doi.org/10.3350/cmh.2013.19.2.190

Citations

Citations to this article as recorded by  Crossref logo
  • Abemaciclib-associated kidney injuries: A retrospective analysis of the United States Food and Drug Administration adverse events reporting system
    Xiangchun Xu, Xuzheng Guo, Jinhui Chen, Yuhua Pan, Jing Li, Jing Chen, Weihua Lai, Lu Lin
    Journal of International Medical Research.2025;[Epub]     CrossRef
  • ¿Qué sabemos de la pseudocirrosis? El papel del radiólogo
    E. Canales Lachén, M.Á. Gómez-Bermejo, B. Mateos Muñoz, A. Salgado-Parente, A. Villanueva Campos
    Radiología.2025; : 501705.     CrossRef
  • Pseudocirrhosis: A Case Series with Clinical and Radiographic Correlation and Review of the Literature
    Gal Sadlik, Redmond-Craig Anderson, Xiaomeng Lei, Steven Yong Cen, Vinay A. Duddalwar, Tse-Ling Fong
    Digestive Diseases and Sciences.2024; 69(3): 1004.     CrossRef
  • The Clinical Features and Outcomes of Pseudocirrhosis in Breast Cancer
    Edward Phillips, Mantegh Sethi, Surammiya Vasanthakumar, Gina Sherpa, Stephen Johnston, Marina Parton, Emma Kipps, Nicholas C. Turner, Matthew Foxton, Alicia Okines
    Cancers.2024; 16(16): 2822.     CrossRef
  • MRI findings of newly present benign focal hepatic observations following chemotherapy: distinct features in early- and late-term follow-up
    Yiqi Wang, Siyue Mao, Runqian Huang, Sheng Li, Rongzhen Luo, Jingxian Shen
    European Radiology.2024; 35(5): 2783.     CrossRef
  • Clinical characteristics and outcomes in patients with metastatic breast cancer and pseudocirrhosis: a single center retrospective cohort study
    Laura A. Huppert, Zak Walker, Moming Li, Mi-Ok Kim, Jennifer Callan, Danielle Brandman, Melanie Majure, Michelle E. Melisko, Hope S. Rugo, Spencer Behr, A. Jo Chien
    Breast Cancer Research and Treatment.2023; 197(1): 137.     CrossRef
  • Growth Pattern of Hepatic Metastasis as a Prognostic Index Reflecting Liver Metastasis-Associated Survival in Breast Cancer Liver Metastasis
    Jieun Lee, Moonhyung Choi, Seungyeon Joe, Kabsoo Shin, Sung-Hak Lee, Ahwon Lee
    Journal of Clinical Medicine.2022; 11(10): 2852.     CrossRef
  • Pseudocirrhosis and portal hypertension in patients with metastatic cancers: a systematic review and meta-analysis
    Rosanna Villani, Francesca Di Cosimo, Moris Sangineto, Antonino Davide Romano, Gaetano Serviddio
    Scientific Reports.2022;[Epub]     CrossRef
  • Pseudocirrhosis in Breast Cancer – Experience From an Academic Cancer Center
    Dharmesh Gopalakrishnan, Ain Shajihan, Andrei S. Purysko, Jame Abraham
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Imaging of the chemotherapy-induced hepatic damage: Yellow liver, blue liver, and pseudocirrhosis
    Linda Calistri, Vieri Rastrelli, Cosimo Nardi, Davide Maraghelli, Sofia Vidali, Michele Pietragalla, Stefano Colagrande
    World Journal of Gastroenterology.2021; 27(46): 7866.     CrossRef
  • Pseudocirrhosis after chemotherapy for gastric cancer with diffuse liver metastases: A case report
    Tomohito Shinoda, Toshiyuki Tanahashi, Takuji Sakuratani, Masato Ota, Seito Fujibayashi, Shunya Kiriyama, Keita Matsumoto, Kazunori Yawata, Yoshiyuki Sasaki, Shinji Osada, Makoto Yamada
    Molecular and Clinical Oncology.2021;[Epub]     CrossRef
  • Pseudocirrhosis due to liver metastasis from lung adenocarcinoma
    Naoki Shijubou, Toshiyuki Sumi, Yoshiko Keira, Hideaki Shiraishi, Yuta Nagahisa, Keigo Matsuura, Motoki Sekikawa, Yuichi Yamada, Hisashi Nakata, Hirofumi Chiba
    Thoracic Cancer.2021; 12(17): 2407.     CrossRef
  • Other types of diffuse liver disease: is there a way to do it?
    Hilton Leao Filho, Camila Vilela de Oliveira, Natally Horvat
    Abdominal Radiology.2020; 45(11): 3425.     CrossRef
  • Transitional Cell Carcinoma and Pseudocirrhosis— A Case Report and Review of the Literature
    Gilad Borisovsky, Daniel A. Goldstein, Noa Eliakim-Raz, Shlomit R. Tamir
    Journal of Gastrointestinal and Abdominal Radiology.2020; 3(S 01): S73.     CrossRef
  • Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
    Meritxell Bellet, Faten Ahmad, Rafael Villanueva, Carolina Valdivia, Julián Palomino-Doza, Ada Ruiz, Xavier Gonzàlez, Encarna Adrover, Analía Azaro, Maria Valls-Margarit, Josep Lluís Parra, Juan Aguilar, Maria Vidal, Anastasi Martín, Joaquín Gavilá, Santi
    Therapeutic Advances in Medical Oncology.2019;[Epub]     CrossRef
  • Clinical features of pseudocirrhosis in metastatic breast cancer
    Caspian Oliai, Michael L. Douek, Caelainn Rhoane, Abhishek Bhutada, Phillip S. Ge, Bruce A. Runyon, Xiaoyan Wang, Sara A. Hurvitz
    Breast Cancer Research and Treatment.2019; 177(2): 409.     CrossRef
  • CT and MR imaging of chemotherapy-induced hepatopathy
    Federica Vernuccio, Marco Dioguardi Burgio, Filippo Barbiera, Silvestro Cusmà, Giuseppe Badalamenti, Massimo Midiri, Valérie Vilgrain, Giuseppe Brancatelli
    Abdominal Radiology.2019; 44(10): 3312.     CrossRef
  • Recurrent metastatic breast cancer presenting with portal hypertension and pseudocirrhosis
    Maciej Adler, Ivan Tang, Michael William Gach, George MacFaul
    BMJ Case Reports.2019; 12(11): e231044.     CrossRef
  • Pseudocirrhosis after chemotherapy in breast cancer, case reports
    Tomoyoshi Aoyagi, Kazuaki Takabe, Tamaki Tamanuki, Hisahiro Matsubara, Hiroshi Matsuzaki
    Breast Cancer.2018; 25(5): 614.     CrossRef
  • Pseudocirrhosis in a Patient with New-Onset Dysphagia and History of Ovarian Carcinoma
    Andrew Zanazanian, Amir Kalani, James H. Tabibian
    ACG Case Reports Journal.2018; 5(1): e29.     CrossRef
  • Pseudocirrhosis caused by regorafenib in an advanced rectal cancer patient with multiple liver metastases
    Kensuke Kumamoto, Shungo Endo, Noriyuki Isohata, Azuma Nirei, Daiki Nemoto, Kenichi Utano, Takuro Saito, Kazutomo Togashi
    Molecular and Clinical Oncology.2017; 6(1): 63.     CrossRef
  • Pseudocirrhosis: A Case Series and Literature Review
    Abimbola Adike, Nina Karlin, Christine Menias, Elizabeth J. Carey
    Case Reports in Gastroenterology.2016; 10(2): 381.     CrossRef
  • Pseudocirrhosis in Gastric Cancer with Diffuse Liver Metastases after a Dramatic Response to Chemotherapy
    Seiichiro Mitani, Shigenori Kadowaki, Hiroya Taniguchi, Hisanori Muto, Kei Muro
    Case Reports in Oncology.2016; 9(1): 106.     CrossRef
  • Cancer therapy related complications in the liver, pancreas, and biliary system: an imaging perspective
    Danny Ngo, Jemianne Bautista Jia, Christopher S. Green, Anjalie T. Gulati, Chandana Lall
    Insights into Imaging.2015; 6(6): 665.     CrossRef
  • Extra-mammary findings on breast MRI: a pictorial review
    Norna L. Karp, Elissa R. Price, Dorota J. Wisner, C. Belinda Chang, Nola M. Hylton, Bonnie N. Joe
    Clinical Imaging.2015; 39(4): 547.     CrossRef
  • Chemotherapy induced liver abnormalities: an imaging perspective
    Ankush Sharma, Roozbeh Houshyar, Priya Bhosale, Joon-Il Choi, Rajesh Gulati, Chandana Lall
    Clinical and Molecular Hepatology.2014; 20(3): 317.     CrossRef
  • Imaging of Chemotherapy-related Iatrogenic Abdominal and Pelvic Conditions
    Chitra Viswanathan, Mylene Truong, Tara Sagebiel, Naveen Garg, Priya Bhosale
    Radiologic Clinics of North America.2014; 52(5): 1029.     CrossRef
  • 12,059 View
  • 130 Download
  • Crossref

Liver Pathology

Benign liver tumors and cystic disease of liver

Reactive lymphoid hyperplasia of the liver
Woo Sung Moon, Keum Ha Choi
Korean J Hepatol 2013;19(1):87-91.
Published online March 25, 2013
DOI: https://doi.org/10.3350/cmh.2013.19.1.87

Citations

Citations to this article as recorded by  Crossref logo
  • Clinical features, natural history and outcomes of pseudolymphoma of liver: A case-series and systematic review
    Wei Jiang, Dongbo Wu, Qin Li, Chang-Hai Liu, Qingmin Zeng, Enqiang Chen, Changli Lu, Hong Tang
    Asian Journal of Surgery.2023; 46(2): 841.     CrossRef
  • A case of reactive lymphoid hyperplasia of the liver in a patient with autoimmune hepatitis
    Hiroki Kanno, Hisamune Sakai, Toru Hisaka, Satoki Kojima, Ryuta Midorikawa, Shogo Fukutomi, Yoriko Nomura, Yuichi Goto, Toshihiro Sato, Munehiro Yoshitomi, Ryuichi Kawahara, Koji Okuda
    Surgical Case Reports.2020;[Epub]     CrossRef
  • Contrast‐Enhanced Ultrasound Features of Hepatic Reactive Lymphoid Hyperplasia: Correlation With Histopathologic Findings
    Cai‐hong Dong, Qing Lu, Wen‐ping Wang, Zheng‐biao Ji, Xi Wang
    Journal of Ultrasound in Medicine.2019; 38(9): 2379.     CrossRef
  • Hepatic Pseudolymphoma with an Occult Hepatitis B Virus Infection
    Hideo Kunimoto, Daisuke Morihara, Shin-ichiro Nakane, Takashi Tanaka, Keiji Yokoyama, Akira Anan, Yasuaki Takeyama, Makoto Irie, Satoshi Shakado, Tomoaki Noritomi, Morishige Takeshita, Kengo Yoshimitsu, Shotaro Sakisaka
    Internal Medicine.2018; 57(2): 223.     CrossRef
  • Intrahepatic Reactive Lymphoid Hyperplasia: A Case Report and Review of the Literature
    Samantha Seitter, Zachary D. Goodman, Theodore M. Friedman, Timothy R. Shaver, George Younan
    Case Reports in Surgery.2018; 2018: 1.     CrossRef
  • Hepatic Pseudolymphoma Mimicking a Hypervascular Tumor: A Case Report
    Bora Im, Suk Ki Jang, Jae Woo Yeon, So Ya Paik, Sang Jong Park, Hyuk Jung Kim
    Journal of the Korean Society of Radiology.2018; 79(6): 348.     CrossRef
  • A Case of Hepaticreactive Lymphoid Hyperplasia Mimicking Hepatic Metastasis of Gastric Cancer
    Masashi HASHIMOTO, Yusuke MATSUMOTO, Ikumi HAMANO, Yoshikatsu ENDO, Kyohei KAI, Shizo SATO, Machiko HOTTA
    Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2017; 78(5): 1060.     CrossRef
  • Pseudolymphoma of the liver: a case report and literature review
    Kazuhiro Taguchi, Shintaro Kuroda, Tsuyoshi Kobayashi, Hirotaka Tashiro, Kohei Ishiyama, Kentaro Ide, Masahiro Ohira, Hiroyuki Tahara, Koji Arihiro, Hideki Ohdan
    Surgical Case Reports.2015;[Epub]     CrossRef
  • Reactive Lymphoid Hyperplasia Treated with Radiofrequency Ablation
    Seo Hwa Park, Eun Gyu Kang, Min Wook Kim, Hyun Soo Kim, Jeong Kwon Kim
    Korean Journal of Medicine.2015; 88(2): 177.     CrossRef
  • Reactive Lymphoid Hyperplasia of the Liver Mimicking Liver Metastasis in a Patient with Cecal Cancer
    Gaku OTA, Koji KOINUMA, Kazue MORISHIMA, Hisanaga HORIE, Naohiro SATA, Toru TANAKA
    Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2015; 76(10): 2493.     CrossRef
  • Hepatic mass with lymphadenopathy in a B viral hepatitis patient
    Ji Soo Song, Hee Chul Yu, Woo Sung Moon
    Liver International.2014;[Epub]     CrossRef
  • 13,122 View
  • 87 Download
  • 9 Web of Science
  • Crossref

Review

Drug induced liver injury

Drug-induced liver injury: present and future
Ki Tae Suk, Dong Joon Kim
Korean J Hepatol 2012;18(3):249-257.
Published online September 25, 2012
DOI: https://doi.org/10.3350/cmh.2012.18.3.249

Liver injury due to prescription and nonprescription medications is a growing medical, scientific, and public health problem. Worldwide, the estimated annual incidence rate of drug-induced liver injury (DILI) is 13.9-24.0 per 100,000 inhabitants. DILI is one of the leading causes of acute liver failure in the US. In Korea, the annual extrapolated incidence of cases hospitalized at university hospital is 12/100,000 persons/year. Most cases of DILI are the result of idiosyncratic metabolic responses or unexpected reactions to medication. There is marked geographic variation in relevant agents; antibiotics, anticonvulsants, and psychotropic drugs are the most common offending agents in the West, whereas in Asia, 'herbs' and 'health foods or dietary supplements' are more common. Different medical circumstances also cause discrepancy in definition and classification of DILI between West and Asia. In the concern of causality assessment, the application of the Roussel Uclaf Causality Assessment Method (RUCAM) scale frequently undercounts the cases caused by 'herbs' due to a lack of previous information and incompatible time criteria. Therefore, a more objective and reproducible tool that could be used for the diagnosis of DILI caused by 'herbs' is needed in Asia. In addition, a reporting system similar to the Drug-Induced Liver Injury Network (DILIN) in the US should be established as soon as possible in Asia.

Citations

Citations to this article as recorded by  Crossref logo
  • IC-MAC: A novel NIR fluorescent probe for monitoring the glutathione fluctuations in drug-induced liver injury
    Xiao Li, Chengqing Zhao, Zhiyuan Wang, Suntao Shi, Huiling Gao, Jiang Wu, Baoxin Zhang
    Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy.2026; 347: 126980.     CrossRef
  • Association of Gene Polymorphisms and Serum Levels of ALAS1 with the Risk of Anti‐Tuberculosis Drug‐Induced Liver Injury
    Bing Han, Yiwen He, Min Zhu, Meiling Zhang, Lihuan Lu, Xiaoyan Xu, Xiaomin He, Honggang Yi, Shaowen Tang
    The Journal of Clinical Pharmacology.2025; 65(2): 197.     CrossRef
  • Merestinib inhibits cuproptosis by targeting NRF2 to alleviate acute liver injury
    Xianyu Luo, Maoyuan Linghu, Xinru Zhou, Yi Ru, Qian Huang, Didi Liu, Shurong Ji, Yinchu Ma, Yingli Luo, Yi Huang
    Free Radical Biology and Medicine.2025; 229: 68.     CrossRef
  • Drug-Induced Liver Injury Associated with Turmeric and Piperine: A Case and Review
    Atul Shrestha, Sarah Elliott, Joshua Haron Abasszade, Kyle Wu, Thomas Worland, Ian Simpson, Anouk Dev
    Case Reports in Gastroenterology.2025; 19(1): 96.     CrossRef
  • A Rare Case of Drug-Induced Liver Injury (DILI) From Topiramate
    Raymart Macasaet, FNU Payal, Karan Yagnik, Malay Rathod, David Aquino, Shilpan Shah
    Cureus.2025;[Epub]     CrossRef
  • Application of humanized mice to toxicology studies: properties of chimeric mice with humanized liver (PXB-mice) for hepatotoxicity
    Nazneen Sultana, Takeshi Izawa, Tomomi Kamei, Sho Fujiwara, Yuri Ito, Yuki Takami, Mitsuru Kuwamura
    Journal of Toxicologic Pathology.2025; 38(2): 183.     CrossRef
  • The Hepatoprotective Effects of Ginsenoside from Ginseng: A Review of Molecular Mechanisms and Therapeutic Potentials
    Seyed Reza Taha, Andarz Fazlollahpour-Naghibi, Mahdieh Shariat Zadeh, Kimia Bagheri, Hamed Rahmani Youshanlouei, Reza Mosaddeghi-Heris, Seyyed Sina Hejazian, Amirreza Khalaji, Seyedeh Shaghayegh Alavi, Payam Fattahi, Saba Mehrtabar
    Current Pharmaceutical Biotechnology.2025; 26(7): 957.     CrossRef
  • iDILI-MT: identifying drug-induced liver injury compounds with a multi-head Transformer
    Wanrong Zheng, Fobao Lai
    PeerJ Computer Science.2025; 11: e2973.     CrossRef
  • Network toxicology and cell experiments reveal the mechanism of saikochromone A-induced hepatotoxicity
    Ying Zhang, Fengmei Li, Xiang Ji, Limin Shao, Qian Lyu, Qi Shao
    Toxicon.2025; 267: 108588.     CrossRef
  • Complementary and Alternative Medicine-Induced Combined Hepatorenal Toxicity: A Case Report
    George S Zacharia, Vedashree Ravte, Abhilasha Jyala, Elona Shehi
    Cureus.2025;[Epub]     CrossRef
  • A computational study to identify Sesamol derivatives as NRF2 activator for protection against drug-induced liver injury (DILI)
    Ajay Mili, Sumit Birangal, Krishnadas Nandakumar, Richard Lobo
    Molecular Diversity.2024; 28(3): 1709.     CrossRef
  • Predicting drug-induced liver injury using graph attention mechanism and molecular fingerprints
    Jifeng Wang, Li Zhang, Jianqiang Sun, Xin Yang, Wei Wu, Wei Chen, Qi Zhao
    Methods.2024; 221: 18.     CrossRef
  • InterDILI: interpretable prediction of drug-induced liver injury through permutation feature importance and attention mechanism
    Soyeon Lee, Sunyong Yoo
    Journal of Cheminformatics.2024;[Epub]     CrossRef
  • Novel fast dissolving freeze dried sublingual baicalin tablets for enhanced hepatoprotective effect: in-vitro characterization, cell viability, and in-vivo evaluation
    Farida N. Abdelrazek, Rodayna A. Shalaby, Sally A. Fahim, Reham M. Essam, Shady E. Anis, Yasmin M. Attia, Nevine S. Abd El Malak
    Pharmaceutical Development and Technology.2024; 29(4): 371.     CrossRef
  • Peroxynitrite imaging in ferroptosis-mediated drug-induced liver injury with a near-infrared fluorescence probe
    Ruixin Liu, Haijing Jiang, Wenjie Yang, Zhijuan Zheng, Xiaoming Wang, Zhenhua Tian, Danyang Wang, Dongfang Kan, Dan Zhang, Zhixin Tang
    Analytica Chimica Acta.2024; 1309: 342673.     CrossRef
  • Hepatic injury and hepatic failure adverse events in 3,4-methylenedioxymethamphetamine users reported to the FDA Adverse Event Reporting System
    Tigran Makunts, Ruben Abagyan
    Frontiers in Psychiatry.2024;[Epub]     CrossRef
  • Network Pharmacology Prediction and Experimental Validation of Ferulic Acid’s Protective Effects against Diclofenac‐Induced Liver Injury
    Fatema S. Alatawi, Awatif M. E. Omran, Mohsen S. Alatawi, Eman Rashad, Noha A. E. Yasin, Ahmed F. Soliman, Ignazio Restivo
    Journal of Food Biochemistry.2024;[Epub]     CrossRef
  • Neddylation inhibition prevents acetaminophen-induced liver damage by enhancing the anabolic cardiolipin pathway
    Clàudia Gil-Pitarch, Marina Serrano-Maciá, Jorge Simon, Laura Mosca, Carolina Conter, Claudia M. Rejano-Gordillo, L. Estefanía Zapata-Pavas, Patricia Peña-Sanfélix, Mikel Azkargorta, Rubén Rodríguez-Agudo, Sofía Lachiondo-Ortega, Maria Mercado-Gómez, Tere
    Cell Reports Medicine.2024; 5(7): 101653.     CrossRef
  • Toward an Explainable Large Language Model for the Automatic Identification of the Drug-Induced Liver Injury Literature
    Chunwei Ma, Russell D. Wolfinger
    Chemical Research in Toxicology.2024; 37(9): 1524.     CrossRef
  • Cefepime-Induced Mixed Hepatocellular and Cholestatic Liver Injury: A Case Report
    Mahyar Toofantabrizi, Anuj Timshina, Raj M Dongol
    Cureus.2024;[Epub]     CrossRef
  • GRK2 mediates cisplatin-induced acute liver injury via the modulation of NOX4
    Qianlei Wang, Mengyang Li, Fei Duan, Kangjun Xiao, Qing Qing Sun, Jiang rui Cheng, Lei Ni, Zhengkun Xu, Bingfa Xu, Feng Xiao, Jiajie Kuai, Wei Wei, Chun Wang
    Cell Biology and Toxicology.2024;[Epub]     CrossRef
  • Prediction of bioactive compounds hepatotoxicity using in silico and in vitro analysis
    Kwanyong Choi, Soyeon Lee, Sunyong Yoo, Hyoung-Yun Han, Soo-yeon Park, Ji Yeon Kim
    Applied Biological Chemistry.2024;[Epub]     CrossRef
  • The relationship between relative telomere length and anti-tuberculosis drug-induced hepatitis : A case-control study
    Wenpei Liu, Nannan Wang, Jia Zhu, Meiling Zhang, Lihuan Lu, Hongqiu Pan, Xiaomin He, Honggang Yi, Shaowen Tang
    Therapies.2023; 78(3): 259.     CrossRef
  • Remdesivir-Associated Acute Liver Failure in a COVID-19 Patient: A Case Report and Literature Review
    Mohammad A Ahmed-Khan, George Matar, Kyle Coombes, Kayvon Moin, Bishoy M Joseph, Carly M Funk
    Cureus.2023;[Epub]     CrossRef
  • Molecular Mechanisms of Hepatotoxicity
    Antonietta Messina, Jean-Charles Duclos-Vallée
    International Journal of Molecular Sciences.2023; 24(4): 3791.     CrossRef
  • Drug-Induced Liver Injury in Tuberculosis: Mechanisms of Development and Diagnostic Methods
    D. S. Sukhanov, E. V. Timofeev, Yu. S. Alekseeva, D. Yu. Azovtsev
    Juvenis Scientia.2023; 9(1): 24.     CrossRef
  • Hepatoprotective Properties of Cuminum cyminum Seeds Powder as Post-Treatment for Acetaminophen-Induced Injury
    Afsaneh Mozaffarinia, Ali Gol, Aghileh Mohammadzadeh
    Journal of Advances in Medical and Biomedical Research.2023; 31(145): 170.     CrossRef
  • Protection of Liver Functions and Improvement of Kidney Functions by Twelve Weeks Consumption of Cuban Policosanol (Raydel®) with a Decrease of Glycated Hemoglobin and Blood Pressure from a Randomized, Placebo-Controlled, and Double-Blinded Study with Hea
    Kyung-Hyun Cho, Ji-Eun Kim, Tomohiro Komatsu, Yoshinari Uehara
    Life.2023; 13(6): 1319.     CrossRef
  • Genetic and Epigenetic Basis of Drug-Induced Liver Injury
    Snigdha Singh, P.V.S.N. Kiran Kumar, J. Pradeep Kumar, Sojit Tomo, Dharamveer Yadav, Praveen Sharma, Mahadev Rao, Mithu Banerjee
    Seminars in Liver Disease.2023; 43(02): 163.     CrossRef
  • Cell-Membrane-Localizing Fluorescence Probes for Aminopeptidase N
    Yun Jae Yang, Mingchong Dai, Kyo Han Ahn
    ACS Sensors.2023; 8(7): 2791.     CrossRef
  • Hepatic Effect of 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside, the Signature Component of Traditional Chinese Medicine Heshouwu: Advances and Prospects
    Cheng-Yu Wang, Ying-Huan Hu, Zhen-Xiao Sun
    Current Drug Metabolism.2023; 24(1): 16.     CrossRef
  • Shifting perspectives in liver diseases after kidney transplantation
    Iva Kosuta, Ana Ostojic, Ana Vujaklija Brajkovic, Jaksa Babel, Bojana Simunov, Maja Sremac, Anna Mrzljak
    World Journal of Hepatology.2023; 15(7): 883.     CrossRef
  • Liquiritigenin Confers Liver Protection by Enhancing NRF2 Signaling through Both Canonical and Non-canonical Signaling Pathways
    Mengjiao Shi, Jian Zhang, Miaomiao Li, Yaping Zhao, Ying Guo, Jiayi Xu, Rongrong Liu, Zongfang Li, Dongmei Ren, Pengfei Liu
    Journal of Medicinal Chemistry.2023; 66(16): 11324.     CrossRef
  • Cyclopia intermedia E. Mey protects against ROS-induced liver injury in HepG2/C3A cells.
    Shanika Reddy, Khaled Rashed, Jeanine L. Marnewick, Fanie G. Rautenbach, Trevor Koekemoer, Maryna van de Venter
    South African Journal of Botany.2023; 162: 794.     CrossRef
  • MAGPIX and FLEXMAP 3D Luminex platforms for direct detection of miR-122-5p through dynamic chemical labelling
    Antonio Marín-Romero, Valerie Regele, Dajana Kolanovic, Manuela Hofner, Juan José Díaz-Mochón, Christa Nöhammer, Salvatore Pernagallo
    The Analyst.2023; 148(22): 5658.     CrossRef
  • A Case Report of UDCA and Injinho-tang Co-administration for Liver Damage Caused by Rifampin
    Seyeon Lee, Hansung Yoon, Kibeom Ku, Mariah Kim, Irang Nam, Minhwa Kim, Changwoo Han
    The Journal of Internal Korean Medicine.2023; 44(5): 1011.     CrossRef
  • Metabolomic markers predictive of hepatic adaptation to therapeutic dosing of acetaminophen
    Brandon J. Sonn, Kennon J. Heard, Susan M. Heard, Angelo D’Alessandro, Kate M. Reynolds, Richard C. Dart, Barry H. Rumack, Andrew A. Monte
    Clinical Toxicology.2022; 60(2): 221.     CrossRef
  • Evolution of 3D bioprinting-from the perspectives of bioprinting companies
    Dongxu Ke, Changmei Niu, Xi Yang
    Bioprinting.2022; 25: e00193.     CrossRef
  • Exploring Indicators of Hepatotoxicity-Related Post-Marketing Regulatory Actions: A Retrospective Analysis of Drug Approval Data
    Salwa M. Almomen, Mona A. Almaghrabi, Saja M. Alhabardi, Adel A. Alrwisan
    Saudi Journal of Health Systems Research.2022; 2(1): 27.     CrossRef
  • Incidence of Elevated Aminotransferases With or Without Bilirubin Elevation During Treatment With Immune Checkpoint Inhibitors: A Retrospective Study of Patients From Community Oncology Clinics in the United States
    Christopher Kim, Shao Zu, Hosein Kouros-Mehr, Sophia Khaldoyanidi
    Cureus.2022;[Epub]     CrossRef
  • The role of the genetic variant FECH rs11660001 in the occurrence of anti‐tuberculosis drug‐induced liver injury
    Meiling Zhang, Jia Zhu, Nannan Wang, Wenpei Liu, Lihuan Lu, Hongqiu Pan, Xiaomin He, Honggang Yi, Shaowen Tang
    Journal of Clinical Pharmacy and Therapeutics.2022; 47(8): 1276.     CrossRef
  • Rational design of dual ratiometric photoacoustic and fluorescent probe for reliable imaging and quantitative detection of endogenous CO during drug-induced liver injury and repair
    Li Liu, Jingyuan Xu, Shuping Zhang, Hui Chen, Liping Wang, Xing-can Shen, Hua Chen
    Sensors and Actuators B: Chemical.2022; 367: 132171.     CrossRef
  • A Comprehensive Review of Experimental Animal Models of Hepatopathy.
    Ramesh Kumar Gupta, Sachin Chaudhary, Abdel-Nasser El-Shorbagi, Udaivir Singh Sara, Prashant Shukla, Sudhansu Ranjan Swain, Jagannath Sahoo, P. N. Murthy P. N. Murthy
    Biomedical and Pharmacology Journal.2022; 15(2): 563.     CrossRef
  • COVID-19: Current Status in Gastrointestinal, Hepatic, and Pancreatic Diseases—A Concise Review
    Jorge Aquino-Matus, Misael Uribe, Norberto Chavez-Tapia
    Tropical Medicine and Infectious Disease.2022; 7(8): 187.     CrossRef
  • Incidence and Temporal Trend of Antituberculosis Drug-Induced Liver Injury: A Systematic Review and Meta-Analysis
    Nannan Wang, Xinyu Chen, Zhuolu Hao, Jia Guo, Xuwen Wang, Xijing Zhu, Honggang Yi, Qingliang Wang, Shaowen Tang, Maoshui Wang
    Journal of Tropical Medicine.2022; 2022: 1.     CrossRef
  • Safety data and withdrawal of hepatotoxic drugs
    Samy Babai, Laurent Auclert, Hervé Le-Louët
    Therapies.2021; 76(6): 715.     CrossRef
  • An ensemble learning approach for modeling the systems biology of drug-induced injury
    Joaquim Aguirre-Plans, Janet Piñero, Terezinha Souza, Giulia Callegaro, Steven J. Kunnen, Ferran Sanz, Narcis Fernandez-Fuentes, Laura I. Furlong, Emre Guney, Baldo Oliva
    Biology Direct.2021;[Epub]     CrossRef
  • Turmeric-Induced Hepatotoxicity: Report of 2 Cases
    Aalam Sohal, Dhuha Alhankawi, Sunny Sandhu, JayaKrishna Chintanaboina
    International Medical Case Reports Journal.2021; Volume 14: 849.     CrossRef
  • Herb-induced liver injury: Systematic review and meta-analysis
    Vinícius Remus Ballotin, Lucas Goldmann Bigarella, Ajacio Bandeira de Mello Brandão, Raul Angelo Balbinot, Silvana Sartori Balbinot, Jonathan Soldera
    World Journal of Clinical Cases.2021; 9(20): 5490.     CrossRef
  • Hepatotoxicity Secondary to Levofloxacin Use
    Ladan Panahi, Salim Surani Surani, George Udeani, Niraj P Patel, Jacob Sellers
    Cureus.2021;[Epub]     CrossRef
  • Comparative hepatoprotective activity of detoxified roots of Plumbago zeylanica L. and Plumbago rosea L. in Wistar rats
    A.R. Akhilraj, Sudhakar Bhat, B. Priyalatha, K.S. Vimala
    Journal of Ayurveda and Integrative Medicine.2021; 12(3): 452.     CrossRef
  • Signal Detection of Potential Hepatotoxic Drugs: Case-Control Study Using Both a Spontaneous Reporting System and Electronic Medical Records
    Hayato Akimoto, Takuya Nagashima, Kimino Minagawa, Takashi Hayakawa, Yasuo Takahashi, Satoshi Asai
    Biological and Pharmaceutical Bulletin.2021; 44(10): 1514.     CrossRef
  • Food and Nutrition in the Pathogenesis of Liver Damage
    Andrea Mega, Luca Marzi, Michael Kob, Andrea Piccin, Annarosa Floreani
    Nutrients.2021; 13(4): 1326.     CrossRef
  • Toxicity risks evaluation of unknown FDA biotransformed drugs based on a multi-objective feature selection approach
    Mohamed Abd Elaziz, Yasmine S. Moemen, Aboul Ella Hassanien, Shengwu Xiong
    Applied Soft Computing.2020; 97: 105509.     CrossRef
  • Drug-Induced Liver Injury Resources and Reporting for the Clinician
    Marisa Isaacson, Michael Babich
    Clinics in Liver Disease.2020; 24(1): 131.     CrossRef
  • Immune dysregulation increases the incidence of delayed‐type drug hypersensitivity reactions
    Dean J. Naisbitt, Anna Olsson‐Brown, Andrew Gibson, Xiaoli Meng, Monday O. Ogese, Arun Tailor, Paul Thomson
    Allergy.2020; 75(4): 781.     CrossRef
  • Drug-Induced Liver Injury in Critically Ill Children Taking Antiepileptic Drugs: A Retrospective Study
    Kannan Sridharan, Amal Al Daylami, Reema Ajjawi, Husain A.M. Al Ajooz
    Current Therapeutic Research.2020; 92: 100580.     CrossRef
  • Presentations, Causes and Outcomes of Drug-Induced Liver Injury in Egypt
    Omkolthoum Alhaddad, Maha Elsabaawy, Eman Abdelsameea, Ayat Abdallah, Ahmed Shabaan, Nermine Ehsan, Ahmed Elrefaey, Dalia Elsabaawy, Mohsen Salama
    Scientific Reports.2020;[Epub]     CrossRef
  • Protective effect of lyophilized sapodilla (Manilkara zapota) fruit extract against CCl4-induced liver damage in rats
    Sara T. Alrashood, Abdulrahman K. Al-Asmari, Abdullah K. Alotaibi, Rajamohamed A. Manthiri, Syed Rafatullah, Rana M. Hasanato, Haseeb A. Khan, Khalid E. Ibrahim, Adil F. Wali
    Saudi Journal of Biological Sciences.2020; 27(9): 2373.     CrossRef
  • Knowledge Mapping of Drug-Induced Liver Injury: A Scientometric Investigation (2010–2019)
    Lixin Ke, Cuncun Lu, Rui Shen, Tingting Lu, Bin Ma, Yunpeng Hua
    Frontiers in Pharmacology.2020;[Epub]     CrossRef
  • Dendrobium nobile Lindl. alkaloids-mediated protection against CCl4-induced liver mitochondrial oxidative damage is dependent on the activation of Nrf2 signaling pathway
    Jinxin Zhou, Ya Zhang, Shiyue Li, Qian Zhou, Yuanfu Lu, Jingshan Shi, Jie Liu, Qin Wu, Shaoyu Zhou
    Biomedicine & Pharmacotherapy.2020; 129: 110351.     CrossRef
  • Ameliorative effect of extract of Tecoma stans (L.) Juss. ex kunth leaves against CCl4 - and acetaminophen—induced liver damage in rats
    C. Larbie, B. O. Emikpe, S. A. Akpor, E. Adams, C. O. Adjei, A. A. Oyagbemi, T. A. Jarikre
    Advances in Traditional Medicine.2020; 20(4): 555.     CrossRef
  • Paper-Based Cell Culture: Paving the Pathway for Liver Tissue Model Development on a Cellulose Paper Chip
    Tarun Agarwal, Mimi R. Borrelli, Pooyan Makvandi, Milad Ashrafizadeh, Tapas Kumar Maiti
    ACS Applied Bio Materials.2020; 3(7): 3956.     CrossRef
  • Amplification-free profiling of microRNA-122 biomarker in DILI patient serums, using the Luminex MAGPIX system
    Antonio Marín-Romero, Mavys Tabraue-Chávez, James W. Dear, Rosario M. Sánchez-Martín, Hugh Ilyine, Juan J. Guardia-Monteagudo, Mario A. Fara, Francisco J. López-Delgado, Juan J. Díaz-Mochón, Salvatore Pernagallo
    Talanta.2020; : 121265.     CrossRef
  • Association Between Nonvitamin K Antagonist Oral Anticoagulants or Warfarin and Liver Injury: A Cohort Study
    Jiaxi Zhao, Joseph E. Blais, Celine S. L. Chui, In-Hye Suh, Esa Y. H. Chen, Wai-Kay Seto, Michael T. Mok, Vincent K. C. Yan, Wallis C.Y. Lau, Ian C. K. Wong, Esther W. Chan
    American Journal of Gastroenterology.2020; 115(9): 1513.     CrossRef
  • Untargeted Metabolomics Reveals Anaerobic Glycolysis as a Novel Target of the Hepatotoxic Antidepressant Nefazodone
    Evelin Krajnc, Michele Visentin, Zhibo Gai, Bruno Stieger, Sophia L. Samodelov, Stephanie Häusler, Gerd A. Kullak-Ublick
    The Journal of Pharmacology and Experimental Therapeutics.2020; 375(2): 239.     CrossRef
  • Hepatic adverse drug reactions in Malaysia: An 18‐year review of the national centralized reporting system
    Fei Yee Lee, Hin‐Seng Wong, Huan‐Keat Chan, Norleen Mohamed Ali, Muhammad Radzi Abu Hassan, Haniza Omar, Noor Aliza Abdul Mutalib
    Pharmacoepidemiology and Drug Safety.2020; 29(12): 1669.     CrossRef
  • The changing epidemiology of liver diseases in the Asia–Pacific region
    Martin C. S. Wong, Jason L. W. Huang, Jacob George, Junjie Huang, Colette Leung, Mohammed Eslam, Henry L. Y. Chan, Siew C. Ng
    Nature Reviews Gastroenterology & Hepatology.2019; 16(1): 57.     CrossRef
  • Optimized protocol for induction of cytochrome P450 enzymes 1A2 and 3A4 in human primary-like hepatocyte cell strain HepaFH3 to study in vitro toxicology
    Sarah Kammerer, Jan-Heiner Küpper, J.-W. Park, A. Krüger, F. Jung
    Clinical Hemorheology and Microcirculation.2019; 70(4): 563.     CrossRef
  • Diagnosing Drug-Induced Liver Injury by Multispectral Optoacoustic Tomography and Fluorescence Imaging Using a Leucine-Aminopeptidase-Activated Probe
    Yong Huang, Yu Qi, Chenyue Zhan, Fang Zeng, Shuizhu Wu
    Analytical Chemistry.2019; 91(13): 8085.     CrossRef
  • A Case Report of Efficacy of Saenggan-tang on a Patient with Drug Induced Liver Injury
    So-yeon An, Seong-hee Joo, So-yeong Hur, Eun-gyeong Jang, Jang-hoon Lee, Young-chul Kim
    The Journal of Internal Korean Medicine.2019; 40(2): 201.     CrossRef
  • Liver X Receptor α–Induced Cannabinoid Receptor 2 Inhibits Ubiquitin‐Specific Peptidase 4 Through miR‐27b, Protecting Hepatocytes From TGF‐β
    Hong Min Wu, Tae Hyun Kim, Ayoung Kim, Ja Hyun Koo, Min Sung Joo, Sang Geon Kim
    Hepatology Communications.2019; 3(10): 1373.     CrossRef
  • MRI-based preclinical discovery of DILI: A lesson from paracetamol-induced hepatotoxicity
    Ireneusz P. Grudzinski, Monika Ruzycka, Andrzej Cieszanowski, Wojciech Szeszkowski, Iwona Badurek, Anna Malkowska, Magdalena Bamburowicz-Klimkowska
    Regulatory Toxicology and Pharmacology.2019; 108: 104478.     CrossRef
  • Hepatic macrophages in drug-induced liver injury
    Zhao Shan, Cynthia Ju
    Liver Research.2019; 3(3-4): 170.     CrossRef
  • Induced pluripotent stem cells for therapy personalization in pediatric patients: Focus on drug-induced adverse events
    Elena Genova, Federica Cavion, Marianna Lucafò, Luigina De Leo, Marco Pelin, Gabriele Stocco, Giuliana Decorti
    World Journal of Stem Cells.2019; 11(12): 1020.     CrossRef
  • Prevalence and Risk Factors for Drug-Induced Liver Injury Among Patients With Rheumatic Diseases Treated With Biological Therapy: A Single-Center Experience
    K. BRAZDILOVA, T. KOLLER, Z. KILLINGER, J. PAYER
    Physiological Research.2019; : S157.     CrossRef
  • Endogenous Antioxidant and LOX-Mediated Systems Contribute to the Hepatoprotective Activity of Aqueous Partition of Methanol Extract of Muntingia calabura L. Leaves against Paracetamol Intoxication
    Zainul Amiruddin Zakaria, Nur Diyana Mahmood, Siti Syariah Mamat, Nurliana Nasir, Maizatul Hasyima Omar
    Frontiers in Pharmacology.2018;[Epub]     CrossRef
  • Herb-Induced Liver Injuries in Developing Nations: An Update
    Cecilia Nwadiuto Amadi, Orish Ebere Orisakwe
    Toxics.2018; 6(2): 24.     CrossRef
  • Botanicals and Hepatotoxicity
    Marina M. Roytman, Peter Poerzgen, Victor Navarro
    Clinical Pharmacology & Therapeutics.2018; 104(3): 458.     CrossRef
  • Application of Dendrimers for the Treatment of Infectious Diseases
    Zandile Mhlwatika, Blessing Atim Aderibigbe
    Molecules.2018; 23(9): 2205.     CrossRef
  • Human hepatocyte systems for in vitro toxicology analysis
    Sarah Kammerer, Jan-Heiner Küpper
    Journal of Cellular Biotechnology.2018; 3(2): 85.     CrossRef
  • Drug and herbal hepatotoxicity: an overview of clinical classifications
    Mária Szántová, Jozef Sedlačko, Martina Jakabovičová
    Vnitřní lékařství.2018; 64(4): 384.     CrossRef
  • A modified multiparametric assay using HepaRG cells for predicting the degree of drug‐induced liver injury risk
    Takafumi Tomida, Hayao Okamura, Tsuyoshi Yokoi, Yoshihiro Konno
    Journal of Applied Toxicology.2017; 37(3): 382.     CrossRef
  • In Vitro Drug-Induced Liver Injury Prediction: Criteria Optimization of Efflux Transporter IC50 and Physicochemical Properties
    Robert W. Yucha, Kan He, Qin Shi, Lining Cai, Yukie Nakashita, Cindy Q. Xia, Mingxiang Liao
    Toxicological Sciences.2017; 157(2): 487.     CrossRef
  • Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment?
    Rolf Teschke, Johannes Schulze, Axel Eickhoff, Gaby Danan
    International Journal of Molecular Sciences.2017; 18(4): 803.     CrossRef
  • Comparison of efficacy of folic acid and silymarin in the management of antiepileptic drug induced liver injury: a randomized clinical trial
    Masoumeh Asgarshirazi, Mamak Shariat, Mahdi Sheikh
    Hepatobiliary & Pancreatic Diseases International.2017; 16(3): 296.     CrossRef
  • In vitro and in vivo study of the application of volvox spheres to co-culture vehicles in liver tissue engineering
    Siou Han Chang, Han Hsiang Huang, Pei Leun Kang, Yu Chian Wu, Ming-Huang Chang, Shyh Ming Kuo
    Acta Biomaterialia.2017; 63: 261.     CrossRef
  • Liver injury after aluminum potassium sulfate and tannic acid treatment of hemorrhoids
    Kenichi Yoshikawa, Reimi Kawashima, Yuki Hirose, Keiko Shibata, Takafumi Akasu, Noriko Hagiwara, Takeharu Yokota, Nami Imai, Akira Iwaku, Go Kobayashi, Hirohiko Kobayashi, Akiyoshi Kinoshita, Nao Fushiya, Hiroyuki Kijima, Kazuhiko Koike, Masayuki Saruta
    World Journal of Gastroenterology.2017; 23(27): 5034.     CrossRef
  • Artificial liver support in pigs with acetaminophen-induced acute liver failure
    Guo-Lin He, Lei Feng, Lei Cai, Chen-Jie Zhou, Yuan Cheng, Ze-Sheng Jiang, Ming-Xin Pan, Yi Gao
    World Journal of Gastroenterology.2017; 23(18): 3262.     CrossRef
  • Successful salvage treatment of acute graft-versus-host disease after liver transplantation by withdrawal of immunosuppression: a case report
    Wei Qiu, Guo-Yue Lv, Chao Jiang, Ping Zhang, Xiao-Dong Sun, Xiao-Ju Shi, Xue-Yan Liu, Guang-Yi Wang
    Korean Journal of Hepato-Biliary-Pancreatic Surgery.2016; 20(1): 38.     CrossRef
  • Clinical and histological features of idiosyncratic liver injury: Dilemma in diagnosis of autoimmune hepatitis
    Ufuk Bariş Kuzu, Erkin Öztaş, Nesrin Turhan, Fatih Saygili, Nuretdin Suna, Hakan Yildiz, Mustafa Kaplan, Muhammet Yener Akpinar, Meral Akdoğan, Sabite Kaçar, Zeki Mesut Yalin Kiliç, Aydin Şeref Köksal, Bülent Ödemiş, Ertuğrul Kayaçetin
    Hepatology Research.2016; 46(4): 277.     CrossRef
  • Systematic Review of Adverse Effects from Herbal Drugs Reported in Randomized Controlled Trials
    Ji Young Lee, Seung Ah Jun, Sung Shin Hong, Yo Chan Ahn, Dong Soo Lee, Chang Gue Son
    Phytotherapy Research.2016; 30(9): 1412.     CrossRef
  • N‐acetylcysteine for non‐paracetamol drug‐induced liver injury: a systematic review
    Mohamed Farouk Chughlay, Nicole Kramer, C. Wendy Spearman, Mahmoud Werfalli, Karen Cohen
    British Journal of Clinical Pharmacology.2016; 81(6): 1021.     CrossRef
  • Beneficial effect of corticosteroids for patients with severe drug‐induced liver injury
    Ping Fang Hu, Pei Qin Wang, Han Chen, Xiao Fan Hu, Qiu Ping Xie, Jian Shi, Lin Lin, Wei Fen Xie
    Journal of Digestive Diseases.2016; 17(9): 618.     CrossRef
  • Research Advances on Hepatotoxicity of Herbal Medicines in China
    Changxiao Liu, Huirong Fan, Yazhuo Li, Xiaohe Xiao
    BioMed Research International.2016; 2016: 1.     CrossRef
  • A Severe Hepatotoxicity by Antituberculosis Drug, and its Recovery in Oriental Hospital
    Chang-Gue Son
    Journal of Korean Medicine.2016; 37(2): 119.     CrossRef
  • Profile of Acute Liver Failure from North-east India and Its Differences from other Parts of the Country
    Premashish Kar, Anup K Das, Tarjina Begum, Anupam Dutta
    Euroasian Journal of Hepato-Gastroenterology.2016; 6(2): 111.     CrossRef
  • I-131 remnant ablation after thyroidectomy induced hepatotoxicity in a case of thyroid cancer
    Rong Lin, Omar Banafea, Jin Ye
    BMC Gastroenterology.2015;[Epub]     CrossRef
  • Development and Regulatory Application of Microrna Biomarkers
    Julian Krauskopf, Marcha Verheijen, Jos C Kleinjans, Theo M de Kok, Florian Caiment
    Biomarkers in Medicine.2015; 9(11): 1137.     CrossRef
  • Drug-induced liver injury in children
    Mansi D. Amin, Sanjiv Harpavat, Daniel H. Leung
    Current Opinion in Pediatrics.2015; 27(5): 625.     CrossRef
  • Clinical Features of Drug-induced Liver Injury According to Etiology
    Byoung Moo Lee, Woong Cheul Lee, Jae Young Jang, Pyoung Ahn, Jin Nyoung Kim, Soung Won Jeong, Eui Ju Park, Sae Hwan Lee, Sang Gyune Kim, Sang-Woo Cha, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim
    Journal of Korean Medical Science.2015; 30(12): 1815.     CrossRef
  • Blood Pyrrole-Protein Adducts—A Biomarker of Pyrrolizidine Alkaloid-Induced Liver Injury in Humans
    Jianqing Ruan, Hong Gao, Na Li, Junyi Xue, Jie Chen, Changqiang Ke, Yang Ye, Peter Pi-Cheng Fu, Jiang Zheng, Jiyao Wang, Ge Lin
    Journal of Environmental Science and Health, Part C.2015; 33(4): 404.     CrossRef
  • La historia oscura de la rosa amarilla: un reporte de caso de toxicidad hepática asociado al consumo de Cochlospermum vitifolium como remedio herbolario
    L. Martínez-Rodriguez, K. Murguía-Hernández, I. García-Juárez, M. Uribe-Esquivel, E. Gómez-Reyes
    Revista de Gastroenterología de México.2015; 80(3): 220.     CrossRef
  • Agomelatine-induced liver injury in a patient with choledocholithiasis
    Piotr Eder, Agnieszka Permoda-Osip, Przemyslaw Majewski, Krzysztof Linke, Janusz K. Rybakowski
    Acta Neuropsychiatrica.2015; 27(1): 56.     CrossRef
  • Association study of UGT1A9 promoter polymorphisms with DILI based on systematically regional variation screen in Chinese population
    J Jiang, X Zhang, R Huo, X Li, Y Yang, Z Gai, M Xu, L Shen, L Cai, C Wan, B Li, L He, S Qin
    The Pharmacogenomics Journal.2015; 15(4): 326.     CrossRef
  • The dark story of the yellow rose: A case report of hepatoxicity associated with Cochlospermum vitifolium consumption as herbal remedy
    L. Martínez-Rodriguez, K. Murguía-Hernández, I. García-Juárez, M. Uribe-Esquivel, E. Gómez-Reyes
    Revista de Gastroenterología de México (English Edition).2015; 80(3): 220.     CrossRef
  • MITOsym®: A Mechanistic, Mathematical Model of Hepatocellular Respiration and Bioenergetics
    Y. Yang, S. Nadanaciva, Y. Will, J. L. Woodhead, B. A. Howell, P. B. Watkins, S. Q. Siler
    Pharmaceutical Research.2015; 32(6): 1975.     CrossRef
  • N-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review protocol
    Mohamed Farouk Chughlay, Nicole Kramer, Mahmoud Werfalli, Wendy Spearman, Mark Emmanuel Engel, Karen Cohen
    Systematic Reviews.2015;[Epub]     CrossRef
  • Autophagy in drug-induced liver toxicity
    Si Chen, William B. Melchior, Yuanfeng Wu, Lei Guo
    Journal of Food and Drug Analysis.2014; 22(2): 161.     CrossRef
  • Predictivity of dog co-culture model, primary human hepatocytes and HepG2 cells for the detection of hepatotoxic drugs in humans
    Franck A. Atienzar, Eric I. Novik, Helga H. Gerets, Amit Parekh, Claude Delatour, Alvaro Cardenas, James MacDonald, Martin L. Yarmush, Stéphane Dhalluin
    Toxicology and Applied Pharmacology.2014; 275(1): 44.     CrossRef
  • Chelidonium majus-Induced Acute Hepatitis
    Sung Gyu Im, Sun Hong Yoo, Dong Ok Jeon, Hyo Jin Cho, Jin Young Choi, Soya Paik, Young Min Park
    The Ewha Medical Journal.2014; 37(1): 60.     CrossRef
  • Efficacy and Tolerability of Benzodiazepines for the Treatment of Behavioral and Psychological Symptoms of Dementia
    Rajesh R. Tampi, Deena J. Tampi
    American Journal of Alzheimer's Disease & Other Dementias®.2014; 29(7): 565.     CrossRef
  • Female gender as a susceptibility factor for drug-induced liver injury
    David E Amacher
    Human & Experimental Toxicology.2014; 33(9): 928.     CrossRef
  • Drug-Induced Cholestasis
    Kalyan Ram Bhamidimarri, Eugene Schiff
    Clinics in Liver Disease.2013; 17(4): 519.     CrossRef
  • Clinical Manifestations and Treatment of Drug-induced Hepatotoxicity
    Christin M. Giordano, Xaralambos B. Zervos
    Clinics in Liver Disease.2013; 17(4): 565.     CrossRef
  • Hepatitis B Virus Inhibits Liver Regeneration Via Epigenetic Regulation of Urokinase-Type Plasminogen Activator
    Eun-Sook Park, Yong Kwang Park, Chan Young Shin, Seung Hwa Park, Sung Hyun Ahn, Doo Hyun Kim, Keo-Heun Lim, So Young Kwon, Kwang Pyo Kim, Sung-Il Yang, Baik L. Seong, Kyun-Hwan Kim
    Hepatology.2013; 58(2): 762.     CrossRef
  • 10.1016/b978-0-323-26339-9.00019-6

    CrossRef Listing of Deleted DOIs.2000;[Epub]     CrossRef
  • 26,138 View
  • 331 Download
  • Crossref

Liver Pathology

Biliary intraepithelial neoplasia: a case with benign biliary stricture
Wonkyung Jung, Baek-hui Kim
Korean J Hepatol 2011;17(4):328-330.
Published online December 26, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.4.328

Citations

Citations to this article as recorded by  Crossref logo
  • Biliary Intraepithelial Neoplasia With Gallbladder Adenoma and Cirrhosis: A Case Report
    William J Chen, Evan Wolff, Chintalapati R Varma, Ramy Shoela
    Cureus.2022;[Epub]     CrossRef
  • Precursor Lesions of Cholangiocarcinoma: A Clinicopathologic Review
    Bita Geramizadeh
    Clinical Pathology.2020;[Epub]     CrossRef
  • A rare case of symptomatic grossly-visible biliary intraepithelial neoplasia mimicking cholangiocarcinoma
    Naohiro Yoshida, Takeshi Aoyagi, Yoshizo Kimura, Yoshiki Naito, Aya Izuwa, Kimihisa Mizoguchi, Kota Ishii, Yu Tanaka, Emi Ohnishi, Shun Miura, Satoshi Shimamura, Nobuhisa Shirahama, Kazuhisa Kaneshiro, Akihiro Saruwatari, Ayako Iwanaga, Yoshihiko Sadakari
    World Journal of Surgical Oncology.2019;[Epub]     CrossRef
  • Successful treatment of biliary intraepithelial neoplasia in the common bile duct via local excision: A case report
    WEI WANG, WEI CHEN, KEWEI LI, JIAN WANG
    Oncology Letters.2016; 11(5): 3142.     CrossRef
  • 7,373 View
  • 49 Download
  • Crossref

Case Report

Osler-Weber-Rendu disease presenting with hepatocellular carcinoma: radiologic and genetic findings
Joo Ho Lee, Yung Sang Lee, Pyo Nyun Kim, Beom Hee Lee, Gu-Whan Kim, Han-Wook Yoo, Nae-Yun Heo, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung, Dong Jin Suh
Korean J Hepatol 2011;17(4):313-318.
Published online December 26, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.4.313

This is a case report of a 68-year-old man with hepatocellular carcinoma (HCC) accompanied by hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu disease, and hepatic vascular malformation. HHT is an autosomal dominant disorder of the fibrovascular tissue that is characterized by recurrent epistaxis, mucocutaneous telangiectasias, and visceral arteriovenous malformations. HHT is caused by mutation of the genes involved in the signaling pathway of transforming growth factor-β, which plays an important role in the formation of vascular endothelia. Hepatic involvement has been reported as occurring in 30-73% of patients with HHT. However, symptomatic liver involvement is quite rare, and the representative clinical presentations of HHT in hepatic involvement are high-output heart failure, portal hypertension, nodular regenerative hyperplasia, and symptoms of biliary ischemia. Some cases of HCC in association with HHT have been reported, but are very rare. We present herein the characteristic radiologic and genetic findings of HHT that was diagnosed during the evaluation and treatment of HCC.

Citations

Citations to this article as recorded by  Crossref logo
  • Abdominal imaging findings of hereditary hemorrhagic telangiectasia: a case series of seven patients and literature review
    Jiawei Liu, Jian Ling, Fen Yu, Lujie Li, Yuxin Wu, Qiaochu Zhao, Chenyu Song, Zhi Dong, Jifei Wang, Mimi Tang, Meicheng Chen, Siya Shi, Yanji Luo, Danyang Xu
    Chinese Journal of Academic Radiology.2025; 8(4): 268.     CrossRef
  • Hepatic manifestations of hereditary haemorrhagic telangiectasia
    Claire Kelly, Elisabetta Buscarini, Guido Manfredi, Stephen Gregory, Michael A. Heneghan
    Liver International.2024; 44(9): 2220.     CrossRef
  • Partial hepatectomy for a patient with Rendu–Osler–Weber disease: a case report
    Naoko Sekiguchi, Daisaku Yamada, Shogo Kobayashi, Kazuki Sasaki, Yoshifumi Iwagami, Yoshito Tomimaru, Takehiro Noda, Hidenori Takahashi, Yuichiro Doki, Hidetoshi Eguchi
    Surgical Case Reports.2023;[Epub]     CrossRef
  • Epidemiology, pathogenesis, diagnosis, surveillance, and management of hepatocellular carcinoma associated with vascular liver disease
    Debi Prasad, Mindie H. Nguyen
    The Kaohsiung Journal of Medical Sciences.2021; 37(5): 355.     CrossRef
  • Benign and malignant hepatocellular lesions in patients with vascular liver diseases
    Valérie Vilgrain, Valérie Paradis, Morgane Van Wettere, Dominique Valla, Maxime Ronot, Pierre-Emmanuel Rautou
    Abdominal Radiology.2018; 43(8): 1968.     CrossRef
  • A successful treatment for hepatocellular carcinoma with Osler–Rendu–Weber disease using radiofrequency ablation under laparoscopy
    Yoshinari Takaoka, Naoki Morimoto, Kouichi Miura, Hiroaki Nomoto, Kozue Murayama, Takuya Hirosawa, Shunji Watanabe, Takeshi Fujieda, Mamiko Ttsukui, Hirotoshi Kawata, Toshiro Niki, Norio Isoda, Makoto Iijima, Hironori Yamamoto
    Clinical Journal of Gastroenterology.2018; 11(6): 501.     CrossRef
  • Osler-Weber-Rendu Disease Presenting as Recurrent Portosystemic Encephalopathy in a 75-year-old Female Patient
    Junghoon Ha, Byoung Kwan Son, Sang Bong Ahn, Young Kwan Jo, Seong Hwan Kim, Yun Ju Jo, Young Sook Park, Yoon Young Jung
    The Korean Journal of Gastroenterology.2015; 65(1): 57.     CrossRef
  • Benign and malignant hepatocellular lesions in patients with vascular liver disease
    Valérie Vilgrain, Pierre-Emmanuel Rautou, Valérie Paradis, Maxime Ronot
    Clinical Liver Disease.2014; 3(6): 122.     CrossRef
  • 12,097 View
  • 65 Download
  • Crossref

Liver Imaging

Focal nodular hyperplasia: with a focus on contrast enhanced ultrasound
Ho Suk Kang, Byung Kook Kim, Chan Sup Shim
Korean J Hepatol 2010;16(4):414-417.
Published online December 31, 2010
DOI: https://doi.org/10.3350/kjhep.2010.16.4.414

Citations

Citations to this article as recorded by  Crossref logo
  • Focal nodular hyperplasia in men: a systematic review
    Adele Gudynaite, Ieva Tveragaite, Povilas Ignatavicius
    HPB.2026;[Epub]     CrossRef
  • Pedunculated Focal Nodular Hyperplasia: When in Doubt, Should We Cut It Out?
    Christos Tsalikidis, Athanasia Mitsala, George Pappas-Gogos, Konstantinos Romanidis, Alexandra K. Tsaroucha, Michail Pitiakoudis
    Journal of Clinical Medicine.2023; 12(18): 6034.     CrossRef
  • Paediatric focal nodular hyperplasia: A case study of typical contrast-enhanced ultrasound findings with quantitative analysis and correlated with magnetic resonance imaging
    Andreas Panayiotou, Vasileios Rafailidis, Annamaria Deganello, Maria Sellars, Paul S Sidhu
    Ultrasound.2021; 29(2): 128.     CrossRef
  • LI-RADS ancillary features on contrast-enhanced ultrasonography
    Christoph F. Dietrich, Yi Dong, Yuko Kono, Cosmin Caraiani, Claude B. Sirlin, Xin-Wu Cui, An Tang
    Ultrasonography.2020; 39(3): 221.     CrossRef
  • 12,066 View
  • 60 Download
  • Crossref

Liver Pathologys

Intrahepatic cholangiocarcinoma associated with Clonorchis sinensis infection
Yoon Mi Jeen , So Young Jin
Korean J Hepatol 2009;15(4):524-527.
Published online December 31, 2009
DOI: https://doi.org/10.3350/kjhep.2009.15.4.524
.

Citations

Citations to this article as recorded by  Crossref logo
  • A Case of Clonorchiasis with Focal Intrahepatic Duct Dilatation Mimicking an Intrahepatic Cholangiocarcinoma
    Bong Gap Kim, Dae Hwan Kang, Cheol Woong Choi, Hyung Wook Kim, Jae Hyung Lee, Suk Hun Kim, Hye Ju Yeo, Soo Yong Lee
    Clinical Endoscopy.2011; 44(1): 55.     CrossRef
  • 5,830 View
  • 39 Download
  • Crossref
Large Liver cell change/dysplasia in hepatitis B virus-related Liver cirrhosis
Haeryoung Kim, M.D., Ph.D., Young Nyun Park, M.D., Ph.D.1
Korean J Hepatol 2009;15(3):375-378.
Published online September 30, 2009
DOI: https://doi.org/10.3350/kjhep.2009.15.3.375
  • 5,123 View
  • 27 Download

Liver Imaging

Focal nodular hyperplasia-Like nodule
Won Jae Lee
Korean J Hepatol 2008;14(4):537-540.
Published online December 31, 2008
DOI: https://doi.org/10.3350/kjhep.2008.14.4.537

Citations

Citations to this article as recorded by  Crossref logo
  • A Case of Multiple Hypervascular Hyperplastic Liver Nodules in a Patient with No History of Alcohol Abuse or Chronic Liver Diseases
    Byoung Joo Do, In Young Park, So Yon Rhee, Jin Kyung Song, Myoung Kuk Jang, Seong Jin Cho, Eun Sook Nam, Eun Joo Yun
    The Korean Journal of Gastroenterology.2015; 65(5): 321.     CrossRef
  • 5,572 View
  • 27 Download
  • Crossref

Liver Pathology

Focal nodular hyperplasia-Like nodule in Liver cirrhosis
Haeryoung Kim, M.D., Ph.D., Young Nyun Park, M.D., Ph.D.1
Korean J Hepatol 2008;14(2):226-230.
Published online June 20, 2008
DOI: https://doi.org/10.3350/kjhep.2008.14.2.226

Citations

Citations to this article as recorded by  Crossref logo
  • Contrast-enhanced Ultrasound—State of the Art in North America
    Richard G. Barr, Stephanie R. Wilson, Andrej Lyshchik, Beth McCarville, Kassa Darge, Edward Grant, Michelle Robbin, Juergen Karl Wilmann, Wui K. Chong, Arthur Fleischer, Harriet J. Paltiel
    Ultrasound Quarterly.2020; 36(4S): S1.     CrossRef
  • 5,300 View
  • 45 Download
  • Crossref

Case Report

A case of ticlopidine induced acute cholestatic hepatitis and pure red cell aplasia
Ji Yeon Lee, M.D., Eun Bum Park, M.D., Jae Hong Ahn, M.D., Sang-jun Suh, M.D., Young Kul Jung, M.D., Ji Hoon Kim, M.D., Bong Kyung Shin, M.D.1, Jin Hyuk Yang, M.D.2, Jong Eun Yeon, M.D., Kwan Soo Byun, M.D.
Korean J Hepatol 2008;14(1):102-107.
Published online March 20, 2008
DOI: https://doi.org/10.3350/kjhep.2008.14.1.102
Ticlopidine inhibits platelet aggregation and provides beneficial secondary prevention of cerebrovascular and coronary artery disease. Frequently reported adverse effects of ticlopidine include diarrhea, nausea, and rash. However, to our knowledge, there are only a few published reports of the simultaneous occurrence of cholestatic hepatitis and pure red cell aplasia. Here we report a patient with simultaneous severe cholestatic hepatitis and pure red cell aplasia associated with ticlopidine. Although these adverse effects are rare, periodic hematological and liver function tests are recommended after starting ticlopidine. (Korean J Hepatol 2008; 14:102-107)

Citations

Citations to this article as recorded by  Crossref logo
  • Acquired pure red cell aplasia due to treatment with clopidogrel: first case report
    Gang Li, Zhao-quan Li, Qi-yu Yang, Jia-dan Yang
    Journal of Thrombosis and Thrombolysis.2014; 38(2): 215.     CrossRef
  • Un caso di epatite colestatica da ticlopidina: descrizione del caso e revisione della letteratura
    Luigi Anastasio, Valerio Manno, Maria Carbone, Nicola Lentini, Sandro Baldari, Lucia Sofia, Giuseppe Topa, Antonio Arone
    Italian Journal of Medicine.2012; 6(3): 216.     CrossRef
  • 6,056 View
  • 31 Download
  • Crossref

Liver Pathology

Intrahepatic Cholangiocarcinoma associated with Hepatolithiasis
Yoon Mi Jeen , So Young Jin
Korean J Hepatol 2007;13(3):423-426.
Published online September 20, 2007
DOI: https://doi.org/10.3350/kjhep.2007.13.3.423
  • 5,727 View
  • 31 Download

Case Reports

Alfuzosin-induced Acute Liver Injury
Seok Yeon Kim, M.D., Byung-Ho Kim, M.D., Seok Ho Dong, M.D., Hyo Jong Kim, M.D., Young Woon Chang, M.D., Rin Chang, M.D., Yoon Wha Kim, M.D.1
Korean J Hepatol 2007;13(3):414-418.
Published online September 20, 2007
DOI: https://doi.org/10.3350/kjhep.2007.13.3.414
We describe a 56-year-old man who developed an acute liver injury after taking alfuzosin for 1 month to control his newly diagnosed benign prostatic hypertrophy (BPH). There was no history of alcohol consumption or the taking herbal or traditional remedies. Viral causes, autoimmune hepatitis, and biliary tree obstruction were excluded. Other rare causes of hepatitis such as hemochromatosis, primary biliary cirrhosis and Wilson’s disease were also absent in this patient. His liver test results began to improve after discontinuing the alfuzosin. Two weeks later, alfuzosin was administered again because the patient complained of dysuria. After 10 days of alfuzosin reuse, his liver test results worsened. Five months later after the complete discontinuation of the drug, his liver test results had returned to normal. This clinical sequence suggests that alfuzosin caused his acute liver injury. (Korean J Hepatol 2007;13:414-418)

Citations

Citations to this article as recorded by  Crossref logo
  • Interactive precision medicine revolution: unleashing a deep learning framework for drug response and recommendation
    Mallikarjuna Rao Gundavarapu, Raghavender Kotla Venkata, S. Bhargavi Latha, Pavan Kumar N. V., Ashlin Deepa R. N., Evgeny Vladimirovich Kotov, Rishi Dev Nautiyal, Laith H. Alzubaidi
    Cogent Engineering.2024;[Epub]     CrossRef
  • Crude extract of Jatobá leaves promotes canine osteosarcoma cell D17 proliferation
    V. S. Vieira, V. S. Cruz, L. L. Nepomuceno, N. P. Soares, E. Arnhold, W. F. P. Teixeira, D. S. Vieira, J. C. A. Borges, F. M. Paixão, E. G. Araújo
    Veterinary World.2022; : 1283.     CrossRef
  • Lower urinary tract symptoms in patients with liver cirrhosis
    Markus Margreiter, Birgit B. Heinisch, Remy Schwarzer, Tobias Klatte, Shahrokh F. Shariat, Arnulf Ferlitsch
    World Journal of Urology.2015; 33(3): 315.     CrossRef
  • Acute Hepatocellular Drug Induced Liver Injury Probably by Alfuzosin
    Tufan Cicek, Huseyin Savas Gokturk, Gulhan Kanat Unler
    Case Reports in Urology.2015; 2015: 1.     CrossRef
  • A case of severe liver injury induced by silodosin
    Norihiro Nomura, Takayoshi Ito, Yasuaki Kanada, Shinichi Shima, Takahiro Hobo, Takahiro Hayashi, Masashi Satou, Dai Sakuma, Junichi Eguchi, Keitarou Mitamura, Yoshio Deguchi, Masaaki Matukawa, Koji Saitou, Haruhiro Inoue
    Kanzo.2014; 55(11): 670.     CrossRef
  • In vitroandin vivoevaluation of a hydrogel-based prototype transdermal patch system of alfuzosin hydrochloride
    Anroop B. Nair, Siva Ram Kiran Vaka, Sumit Gupta, Michael A. Repka, S. Narasimha Murthy
    Pharmaceutical Development and Technology.2012; 17(2): 158.     CrossRef
  • Lesión hepatocelular recurrente por alfuzosina
    José Carlos Titos-Arcos, Hacibe Hallal, Raúl J. Andrade, Aurelio López Martín
    Gastroenterología y Hepatología.2011; 34(2): 125.     CrossRef
  • Detective Work in Drug-Induced Liver Injury: Sometimes It Is All About Interviewing the Right Witness
    A. Sidney Barritt, Joseph Lee, Paul H. Hayashi
    Clinical Gastroenterology and Hepatology.2010; 8(7): 635.     CrossRef
  • Drug-induced liver injury in 2007
    William Norris, Angelo H Paredes, James H Lewis
    Current Opinion in Gastroenterology.2008; 24(3): 287.     CrossRef
  • 6,113 View
  • 38 Download
  • Crossref
A Case of Focal Nodular Hyperplasia of the Liver
heol Su Lim , Su Tek Lee , Dae Ghon Kim , Deuk Soo Ahn , Hee Chul Yu , Baik Hwan Cho
Korean J Hepatol 1997;3(4):337-343.
Focal nodular hyperplasia (FNH) is a rare, benign hepatic tumor which was usually discovered incidentally by imaging procedure performed for some other reasons. FNH is typically asymptomatic and, it seldom bleeds. There is no evidence to support any relation with primary liver cancer. Accordingly, the preferred management is conservative, and excision is reserved for large symptomatic and complicated lesion, or when the diagnosis remains uncertain. Although many cases of FNH has been described to date in the other countries, only four cases of FNH has been reported in Korean literature. In the present report we describe a 7 cm sized asymptomatic lesion of FNH in a 23-year-old woman, that was disclosed by various kinds of imaging procedure. The left lateral segmentectomy was performed. The mass was firm and showed areas of localized growth of mature hepatocytes and septal fibrosis accompanied with marginal ductal proliferation, consistent with FNH. It also displayed an incomplete stellate architectual configration consisted of a central fibrous scar. (Korean J Hepatol 1997;7:337 343)
  • 3,561 View
  • 13 Download
Focal Nodular Hyperplasia with Aberrant Lymphatics -A Case Report-
Kyu Yun Jang1, Woo Sung Moon, 1,4 Baik Hwan Cho,2,4 and Dae Ghon Kim3,4
Korean J Hepatol 1998;4(3):278-282.
Focal nodular hyperplas ia (FNH) is a benig n epithelial tumor of the liver. T he etiology of FNH is unknown, but recent evidence sug ges ts that FNH may represent a localized, hyperplas tic response to a pre- exis ting vascular malformation. T here is a high probability of as sociated les ions , mos t commonly hepatic hemangiomas , mening ioma, as trocytoma, and arterial dysplas ia in various org ans . In the present report we describe a FNH with aberrant lymphatics in a 24- year- old woman. In operation field, lymphatics were located on the s ite of falciform ligament. His tologically, aberrant lymphatics were composed of well vascularized complex lymphatic channels and the mas s were typical FNH. In this case, the role of aberrant lymphatics in the development of FNH was unclear. But as the FNH frequently as sociated with other anomalies, we think the aberrant lymphatic as such anomaly that have not been reported. (Korean J Hepa tol 1998;4:278 282)
  • 3,353 View
  • 12 Download
A Case of Hepatocellular Carcinoma Mimicking Focal Nodular Hyperplasia
Young Eun Joo, Young Ho Seo, Wan Sik Lee, Nam Jin Kim, Hyun Taek Ahn, Kang Seok Seo, Hyun Soo Kim, Jong Sun Rew, Sang Woo Juhng and Sei Jong Kim
Korean J Hepatol 1998;4(4):393-398.
Distinction of hepatocellular carcinoma from benign entities such as focal nodular hyperplasia is important because failure of prompt diagnosis could result in a missed opportunity for curative resection. The differential deagnosis, especially among focal nodular hyperplasia and adenoma and even hepatocellualr carcinoma, may ve difficult; and when using inly a single imaging method, the diagnosis is often equivocal. Therefore, a combination of imaging modalities is preferred. For focal nodular hyperplasia, the combination of computerized tomography (CT ), magnetic resonance imaging (MRI), and radionuclide scintigraphy showed a high sensitivity and specificity. But , histologic examination is required for the differential diagnos is of hepatic mass . We report a case of hepat ocellular carcinoma without clinical evidence of malignancy or serum elevat ion of tumor marker , that mimicked the CT , MRI, and radionuclide scint igraphic appearance of focal nodular hyperplasia. (Korean J Hepatol 1998;4:393 398)
  • 3,136 View
  • 16 Download
A Case of Hereditary Hemorrhagic Telangiectasia
Ji Kyum Kim, M.D., Sung Ho Park, M.D., Ki Hun Kim, M.D., Ho Jong Seo, M.D. Kwang Suk Kim, M.D., Jin Wook Choi, M.D., Ho Jung Kim, M.D., Tae Seob Choi, M.D., Hae Kyung Kim,* M.D. and Jong Suk Kim,* M.D.
Korean J Hepatol 2000;6(4):514-518.
Hereditary hemorrhagic telangiectasia (HHT ) is an autosomal dominant inherited disease characterized by telangiectasias of the skin , mucou s membranes, and various organ sy stem. HHT is not unusual in western countries but there were several reported cases of HHT in Korea. Recently we evaluated a 40- year - old postpartum female who had been suffering from recurrent epistaxis and peripartum dyspnea. T he patient was diagnosed as a HHT complicated by high output heart failure caused by intrahepatic arteriovenous malformation. This case is reported with a review of relevant literature.(Korean J Hepatol 2000 ;6 :5 14 - 5 18)
  • 2,779 View
  • 19 Download
A Case of Focal Nodular Hyperplasia of the Liver
Un Hwi Park, M.D., Chang Min Cho, M.D., Young Doo Lee, M.D., Seung Yeup Lee, M.D., Won Young Tak, M.D., Young Oh Kweon, M.D., Sung Kook Kim, M.D., Yong Hwan Choi, M.D., Joon Mo Chung, M.D., Han Ik Bae, M.D.1 and Hyun Gyu Ryeom, M.D.2
Korean J Hepatol 2000;6(4):524-529.
Focal nodular hyperplasia (FNH) is a rare benign hepatic tumor occurring predominantly in women of childbearing age. Generally oral contraceptive is not associated with FNH but might accentuate the vascular abnormalities which may cause the lesion to enlarge and, very rarely, to rupture. FNH is typically asymptomatic and seldom bleeds. Often it is incidentally observed during imaging procedures performed for some other reasons. The histologic feature of FNH is characterized by areas of localized growth of mature hepatocytes and septal fibrosis. Surgical resection is seldom required because of the benign nature of the lesion and its lack of significant complication. We experienced a case of focal nodular hyperplasia without liver cirrhosis confirmed by surgical resection and histologic examination. in a 47-year-old man. (Korean J Hepatol 2000 ;6 :524 - 529)
  • 3,790 View
  • 15 Download

Original Article

Clinical Features of Surgically Resected Focal Nodular Hyperplasia of the Liver
Nam Cheol Hwang, M.D., Moon Seok Choi, M.D., Joon Hyoek Lee, M.D., Kwang Cheol Koh, M.D., Seung Woon Paik, M.D., Byung Chul Yoo, M.D., Jong Chul Rhee, M.D., Kwang-Woong Lee, M.D.*, Jae-Won Joh, M.D.* and Cheol Keun Park, M.D.
Korean J Hepatol 2004;10(2):135-141.
Background/Aims
Focal nodular hyperplasia (FNH) is a benign hepatic tumor with few serious complications and no malignant transformation. However, differential diagnosis between FNH and other liver tumors, especially hepatocellular carcinoma, is often difficult. Methods: Clinical features of surgically resected FNH were reviewed. From January, 1995 to February, 2003, 10 patients with surgically resected FNH were enrolled. Their age, sex, results of laboratory examination, imaging studies and pathologic findings were evaluated. Results: Median age was 37.5 years and sex ratio (male:female) was 1.5:1. In 5 cases, resection to exclude hepatic adenoma or HCC was performed. Four cases were diagnosed incidentally after surgery. Four patients had risk factors for HCC, such as hepatitis B virus infection, liver cirrhosis or both. The size of FNH was 3.2 2.2 cm. The most common site of the tumor was segment 6 (30.0%). Differential diagnosis with HCC was difficult in 5 of six cases in whom CT was performed. Although needle biopsies were performed preoperatively in 4 cases, it was difficult to distinguish FNH from hepatic adenoma or HCC. Conclusions: FNH was resected due to uncertainty of diagnosis, or incidentally during hepatectomy in patients with other liver disease. In the former, differential diagnosis with hepatic adenoma or HCC was a major problem despite extensive work-up including dynamic CT or biopsy. (Korean J Hepatol 2004;10:135-141)
  • 3,561 View
  • 15 Download

Case Report

A Case of Nodular Regenerative Hyperplasia of Liver that mimicked Primary Biliary Cirrhosis
Sung Gon Shim , Joo Hyun Sohn , Jae Woong Lee , Chang Hee Paik , Young Woo Chung , Jong Pyo Kim , Dong Soo Han , Yong Chul Jeon , Joon Soo Hahm , Dong Hoo Lee , Choon Su
Korean J Hepatol 2004;10(4):313-318.
Nodular regenerative hyperplasia (NRH) of the liver is a rare disease that is characterized by multiple regenerative nodules in the hepatic parenchyma without fibrosis. The exact pathogenesis of NRH has not been established, but it`s been suggested that o
  • 3,343 View
  • 13 Download

Liver Imaging

Hepatic Involvement in Hereditary Hemorrhagic Telangiectasia
Joon Koo Han , Se Hyung Kim
Korean J Hepatol 2004;10(4):322-324.
  • 2,676 View
  • 15 Download

Liver Pathologys

Focal Nodular Hyperplasia
So Young Jin
Korean J Hepatol 2005;11(3):293-297.
  • 3,725 View
  • 14 Download
Nodular Regenerative Hyperplasia
So Young Jin
Korean J Hepatol 2005;11(4):392-395.
  • 2,997 View
  • 12 Download

Liver Imaging

Review

Colorectal Cancer in Inflammatory Bowel Disease
Jonathan Potack , Steven H. Itzkowitz
Korean J Hepatol 2008;12(2):61-73.
Patients with long-standing inflammatory bowel disease have an increased risk of developing colorectal cancer (CRC). CRC risk increases with longer duration of colitis, greater anatomic extent of colitis, the presence of primary sclerosing cholangitis, family history of CRC and severity of inflammation of the colon. Chemoprevention includes aminosalicylates, ursodeoxycholic acid, and possibly folic acid. To reduce CRC mortality in IBD, colonoscopic surveillance remains the major way to detect early mucosal dysplasia. When dysplasia is confirmed, proctocolectomy is considered for these patients. Ulcerative colitis patients with total proctocolectomy and ileal pouch anal-anastomosis have a rather low risk of dysplasia in the ileal pouch, but the anal transition zone should be monitored periodically. New endoscopic and molecular screening approaches may further refine our current surveillance guidelines and our understanding of the natural history of dysplasia.
  • 2,718 View
  • 17 Download
Case Report
Hematochezia with Colonic Polypoid Angiodysplasia in a Young Female Patient
Hong Kyu Choi , Chan Ik Park , Jung Ah Shin , Jong Tae Moon , Se Joon Lee , Chan Il Park , Hyo Jin Park
Korean J Hepatol 2008;12(2):126-129.
A 18-year-old girl visited the hospital due to hematochezia. Colonoscopy revealed a 6-mm Yamada type II polyp with stigmata of bleeding, and a shallow ulcer on top was found at the cecum base. The polyp was removed by snare polypectomy, and hematochezia stopped thereafter. Angiodysplasia was diagnosed histopathologically. Generally, angiodysplasia appears as a flat or elevated, bright-red lesion on endoscopy, with a polypoid shape being extremely rare. This case is significant because the lesion occurred at the youngest reported age and was the smallest that has been reported, and is the only polypoid arteriovenous malformation to be discovered in the cecum.
  • 2,651 View
  • 10 Download